The effect of Cyclopia maculata on AMPK expression in Wistar rats by Jacobs, Carvern Denver
  
  
 
 
 
 
The effect of Cyclopia maculata on AMPK expression in 
Wistar rats 
 
 
 
 
Carvern Denver Jacobs 
 
 
 
Supervisor: Dr Carmen Pheiffer 
Co-supervisor: Prof James Syce 
 
 
November 2012 
 
 
 
 
 
2 
 
Declaration 
 
I Carvern Denver Jacobs do hereby declare that the thesis entitled: 
 
“The effect of Cyclopia maculata on AMPK expression in Wistar rats” 
 
is my own work and submitted in partial fulfillment of the degree Magister Scientiae in 
the South African Herbal Science and Medicine Institute, Faculty of Natural Sciences at 
the University of the Western Cape and that all research resources I have used in this 
thesis have been duly acknowledged by means of complete references. 
 
 
 
 
Name          : Carvern Denver Jacobs 
 
Signature    :  
 
Date            : November 2012 
 
 
 
 
3 
 
Abstract 
Being overweight or obese are major factors contributing to the increased morbidity and 
mortality due to non-communicable diseases such as type 2 diabetes, cardiovascular 
disease and cancer. The treatment of obesity with pharmaceutical drugs is plagued by side 
effects. Plants and their phytochemicals possess a number of beneficial health effects 
including anti-oxidant, anti-mutagenic, anti-inflammatory, anti-obesity and anti-cancer 
effects, mediated by activation of the adenosine monophosphate protein kinase (AMPK). 
AMPK controls many metabolic processes including glucose uptake and utilisation, and 
adipogenesis, and is often referred to as the master regulator establishing cellular 
homeostasis.  
 
Cyclopia maculata, commonly known as honeybush, is an indigenous South Africa plant 
possessing anti-oxidant, anti-inflammatory and anti-cancer properties. Recently, others in 
our laboratory have shown that a hot water extract of fermented C. maculata inhibits 
adipocyte differentiation in 3T3-L1 pre-adipocytes, with some evidence of weight 
regulatory properties in a Wistar rat model of diet-induced obesity.  In the rat study, 21 
day old weanlings were fed a high fat, high sugar cafeteria diet for 3 months with (n=10) 
or without (n=10) C. maculata supplementation. This group of rats was referred to as the 
lean group (n=20). Another group of rats were fed a cafeteria diet for 4 months to induce 
obesity (obese group, n=20) and thereafter treated as described for the lean rats.  The aim 
of this MSc study was to determine whether C. maculata induces AMPK activation. 
 
Proteins were extracted from the liver and muscle tissue of lean and obese Wistar rats 
using an optimized extraction method with a commercial lysis buffer and the TissueLyser. 
Treatment with the C. maculata extract had no effect on the protein yield in lean and 
obese rats. Interestingly, the protein yield in the liver of obese rats was significantly 
higher than that observed in lean rats. Although C. maculata treatment slightly increased 
AMPK activation (calculated as the ratio of phosphorylated AMPK to total AMPK) in the 
liver of lean and obese rats, the difference was not statistical significant. Conversely, C. 
maculata treatment decreased AMPK activity in muscle of lean and obese rats, with 
statistical significance observed in the lean group only (2.3-fold, p<0.05). Differences in 
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AMPK activation between the groups were also noted, a 1.3-fold decreased activity 
observed in obese groups compared to their lean counterparts, although this was not 
statistically significant. Expression of PPARα, a downstream protein target affected by 
AMPK activation was reduced in the liver of lean and obese rats after C. maculata 
treatment. Moreover, PPARα expression was significantly higher in obese compared to 
lean rats (2.7-fold, p<0.001). PPARα is a transcription factor mediating fat metabolism (β-
oxidation) and its expression is induced by circulating free fatty acids, which are 
increased in obese compared to lean rats. The expression of PPARα in muscle was too 
low for Western blot analysis and quantification. 
 
Cyclopia maculata treatment did not affect hepatic expression of UCP2, another protein 
important in establishing energy homeostasis. The expression of UCP2 was 2.9-fold 
higher in the liver of obese rats compared to their lean counterparts, although the 
difference was not statistically significant. The opposite results were observed in the 
muscle where C. maculata treatment decreased UCP2 expression in lean rats (2.8-fold, 
p<0.0001), and UCP2 expression was decreased 1.4-fold in obese rats compared to lean 
rats, although the difference was not statistically significant. 
 
ELISA results for AMPK activation revealed that C. maculata treatment increased AMPK 
activity, although not statistically significant. Histological analysis of retroperitoneal fat 
showed that C. maculata did not affect adipocyte size and number, although a slight 
decrease in adipocyte size was observed after treatment 
 
This study has demonstrated that treatment of the cafeteria diet fed Wistar rats with 300 
mg/kg of a hot water extract of fermented C. maculata does activate AMPK. This study 
revealed important differences between lean and obese rats. In particular, increased 
hepatic protein content, PPARα and UCP2 expression was observed in obese rats 
compared to the lean group. This suggests an adaptive response to the increased 
circulating free fatty acids during obesity and an increase in β-oxidation in these animals. 
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1. Literature review 
1.1 Obesity 
Obesity is said to be the silent plague of the future (Prentice, 2006). Traditionally, 
overweight and obese individuals were thought to exist only in high income countries, 
such as the United States and Great Britain. However, over the last few decades, obesity 
has spiraled into a worldwide epidemic affecting all races, cultures and most countries 
(Flegal et al., 2010). More than 2,500 years ago Hippocrates, the “father of medicine”, 
recognized that people who were overweight were at a higher risk of sudden death. Later, 
in the 18
th
 century, Malcolm Flemyng stated that, “corpulancy” (obesity) may be a disease 
leading to a shorter life span (Haslam and James, 2005). 
 
Being overweight or obese are considered major factors contributing to a reduced 
lifespan, increased morbidity and mortality, as well as an escalating financial burden 
(WHO, 2012). Obesity is characterized by the excessive accumulation of body fat due to 
an imbalance between energy intake and expenditure, i.e., increased consumption of high 
fat, nutrient poor foods and decreased physical activity (Misra and Khurana, 2009).  
 
The body mass index (BMI) is a tool used to define obesity, and is calculated by the 
equation: 
 
BMI = Body weight (kg)/height (m)
2
  
 
Obesity is classified by a BMI of ≥ 30 kg/m2 (WHO, 2012). More recently, abdominal 
circumference and waist-to-hip ratio are considered to be better predictors of obesity and 
metabolic syndrome. Studies in normal weight and obese adults have shown that higher 
abdominal and waist to hip ratios are superior to BMI for predicting increased mortality 
(Reis et al., 2009 and Welborn et al., 2003).  
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The prevalence of obesity has increased dramatically over the last few decades. Finucane 
et al., (2011) estimated that 1.46 billion adults worldwide in 2008 were overweight and 
502 million of these people were obese. It is quite evident that overweight and obesity 
incidences are increasing at a rapid pace, even outdating previous projections of future 
morbidity. The prevalence of overweight and obesity in South Africa is also estimated to 
be very high, with more than 29% of men and 56% of woman classified as overweight or 
obese (Puoane et al., 2002).  Joubert et al., (2007) showed that in 2000, 87% of type 2 
diabetes mellitus (T2DM), 68% of hypertensive disease, 61% of endometrial cancers, 
45% of ischaemic stroke, 38% ischaemic heart disease, 31% of kidney cancer, 24% of 
osteoarthritis, 17% of colon cancer and 13% of postmenopausal breast cancers in South 
Africa were attributable to overweight and obesity.  
 
Figure 1. Worldwide prevalence of overweight.  
Graphical representation of adult overweight prevalence globally in 2008 (Figure taken 
from the Global Health Observatory (GHO), Overweight and obesity, WHO, 2012). 
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Figure 2. Worldwide prevalence of obesity.  
Graphical representation of adult obesity prevalence globally in 2008 (Figure taken from 
the Global Health Observatory (GHO), Overweight and obesity, WHO, 2012). 
 
 
The prevalence of obesity has increased in low and middle income countries at the same 
pace and rate as that in high income countries (Flegal et al., 2010). Urbanization has been 
extensively linked to the increased prevalence of overweight and obesity (Popkin et al., 
2011). Food has also become highly saturated with processed fats, caloric sweetener 
additives and preservatives for a longer shelf life and palatable consumption, increasing 
body weight gain and obesity (Wasir and Misra, 2004). Technological advances in the 
home and at work has led to decreases in manual energy expenditure, which is considered 
one of the major drivers of population weight gain and obesity as well as increased 
morbidity and mortality (Paeratakul et al., 1998). Obesity has a genetic component and a 
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number of genetic variants that increase the risk for obesity has been identified (Loos, 
2011). However, genes alone cannot account for the increasing obesity rates worldwide 
and it is now well known that a complex interaction between environmental factors, such 
as those described above, together with genetic factors play a role in the development of 
this multifactorial disorder.  
 
Obesity places huge financial burdens on countries. Overweight and obese individuals are 
estimated to be responsible for 1% to 3% of the total health care expenditure in most 
countries, with an average of 5% to 10% in the USA as reviewed by Sassi (2010). In 
2008, the estimated medical cost of obesity for the USA was calculated to be $147 billion 
per year (Finkelstein et al., 2009). The percentage is projected to rise to between 16% and 
18 % of the USA health expenditure by 2030 (AHA, 2012). The high costs of obesity are 
especially alarming to health departments of low and middle income countries, such as 
those in Sub-Saharan Africa which are already burdened with infectious diseases such as 
the Human immunodeficiency virus/Acquired immune deficiency syndrome (HIV/AIDS) 
and tuberculosis (TB) (Lalloo and Pillay, 2008).  
 
Being overweight or obese is ranked as the fifth leading risk of global deaths, with a 
mortality incidence of 2.8 million deaths each year (WHO, 2012). The mortality rate from 
obesity associated cardiovascular disease (CVD) deaths in developing countries is 
estimated to increase by 120% for woman and 137% for men, between 1990 and 2020 
(Leeder et al., 2004). 
 
1.2 Metabolic syndrome 
The clustering of metabolic derangements in overweight and obese individuals has been 
collectively classified as the metabolic syndrome (Galassi et al., 2006). Obesity results in 
the deregulation of metabolic processes such as glucose and fat metabolism, leading to the 
development of insulin resistance, hyperglycemia, dyslipidemia and hypertension (Redon 
et al., 2008).  
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Recent epidemiological data has shown that obesity and metabolic syndrome are 
immediate precursors of type 2 diabetes mellitus (T2DM) and CVD (Ford, 2005; Misra 
and Khurana 2009). The metabolic syndrome has been shown to double the risk of CVD 
in patients with hypertension (Andreadis et al., 2007 and Scholze et al., 2010), and triples 
the relative risk of T2DM (Segura et al., 2007). 
 
1.3 Obesity-associated disorders 
The increased prevalence of obesity and metabolic syndrome in developing countries has 
led towards the increased development of non-communicable disease (NCD) such as 
hypertension, asthma, cancer, depression, T2DM and CVD (Scholze et al., 2010; Misra 
and Khurana 2009). Deaths due to NCDs were shown to account for 36 million out of 57 
million deaths globally in 2008, with nearly 80% of these deaths (29 million) occurring in 
low and middle income countries (WHO, 2012). 
 
1.3.1 Insulin resistance 
Insulin resistance occurs when cells become resistant to the action of insulin, reducing the 
uptake of glucose from the circulatory system, resulting in hyperinsulinemia, 
hyperglycemia and dyslipidemia (Samuel et al., 2010). Studies have shown that obesity 
induced insulin resistance occurs independent of genetic heritability (Pi-Sunyer, 2002), 
and are attributable to increased free fatty acids (Schinner et al., 2005 and Samuel et al., 
2010). Hyperinsulinemia and insulin resistance is associated with T2DM, dyslipidemia, 
hypertension, hypercoagulability and CVD (Schinner et al., 2005 and Hemmingsen et al., 
2009). 
 
1.3.2 Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus is defined by high fasting plasma glucose concentrations of ≥ 7.0 
mmol/l (126 mg/dl), and is thought to develop as a consequence of increased peripheral 
insulin resistance and a reduction in the secretion of insulin by the pancreatic β-cells 
(Schinner et al, 2005). The risk of T2DM increases with the extent and duration of 
overweight and with the degree of central obesity (Must et al., 1999 and Kahn et al., 
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2006). Type 2 diabetes was estimated to effect 171 million individuals with an estimated 
increase of 366 million individuals by 2030 (Wild et al., 2004).  
 
1.3.3 Hypertension 
Epidemiological, clinical and animal studies have shown a strong correlation between 
obesity and hypertension (Hall et al., 2003 and Persell, 2011). Abdominal obesity has 
been singled as the most important risk factor for hypertension and CVD (Sironi et al., 
2004). According to the American Heart Association (AHA), about 76.4 million people 
over the age of 20 were estimated to have high blood pressure in the US (AHA, 2012).  
 
1.3.4 Cardiovascular disease (CVD) 
Obesity increases susceptibility to CVD and its related complications (Lavie et al 2009 
and Marinou et al., 2010). CVD associated mortalities were estimated at 17.3 million 
people in 2008, representing 30% of all global deaths (WHO, 2012). Of these deaths, an 
estimated 7.3 million were due to coronary heart disease and 6.2 million were due to 
stroke. 
 
1.4 Obesity therapeutics 
1.4.1 Surgery 
Bariatric surgery or weight loss surgery includes a variety of procedures performed on the 
morbidly obese. Weight loss is achieved by reducing the size of the stomach with 
implanted medical devices (gastric banding), through the removal of a portion of the 
stomach (sleeve gastrectomy or biliopancreatic diversion) or by resecting and rerouting 
the small intestines to a small stomach pouch (gastric bypass surgery) (Porrier et al., 
2011). 
 
These surgical interventions have shown significant long term weight loss, recovery from 
diabetes, improvement of cardiovascular risk factors and a reduction of mortality from 
40% to 23% (Robinson, 2009). Although bariatric surgery can be beneficial it is only 
conducted on the morbidly obese with a huge financial cost and possible surgical 
complications (Encinosa and Hellinger, 2008). 
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1.4.2 Synthetic compounds 
Treatment of obesity with synthetic compounds has been plagued with detrimental side 
effects giving rise to other health complications and morbidities. Phentermine, an appetite 
suppressant was approved for the short term treatment of obesity by the Food and Drug 
Administration (FDA) in the USA in 1959 (Khaodhiar and Apovian, 2007). Thereafter, a 
combination of phentermine and another drug, fenfluramine was sold as “phen-fen”, until 
fenfluramine was withdrawn by the FDA in 1997 due to concerns of developing 
valvoapthy. Another anti-obesity agent, sibutramine, approved in 1997 for the long term 
treatment was withdrawn from the market in 2010 due to an increased risk of nonfatal 
myocardial infarction and stroke in patients with pre-existing CVD and T2DM (James et 
al., 2010).   
 
Currently, Orlistat (Xenical) and Lorcaserin are the only two FDA approved drugs for the 
long term treatment of obesity. Orlistat acts by inhibiting pancreatic and gastric lipase 
enzymes blocking 25% to 30% of fat absorption in the gastrointestinal tract (Torgerson et 
al., 2004). It is considered mild in comparison to appetite suppressants. Lorcaserin acts 
centrally on serotonin receptors promoting the feeling of satiety and reducing food intake 
(Smith et al., 2008(a)). Lorcaserin was proven to function as an anti-obesity drug for 
chronic weight management in the morbidly obese with a BMI ≥ 30 kg/m2 (Smith et al., 
2008(b)).  
 
1.4.3 Natural products 
The use of natural products to treat obesity has gained considerable interest over the last 
decade (Hwang et al., 2009). Phytochemicals and plants are viewed as safe, effective and 
affordable alternatives to synthetic treatments with fewer side effects (Wu et al., 2010). 
Numerous anti-obesity herbal compositions and single compounds purified from plants 
have been shown to regulate body weight gain and obesity (Kang et al., 2012; Lee at al., 
2010; Wu et al., 2010 and Hwang et al., 2009). 
 
Lee et al., (2010) showed that a herbal mixture consisting of seven herbs inhibited fat 
accumulation in vitro and in vivo, through the modulation of the adipogenic pathway. 
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Citrus peel which has been used in Asia for centuries to treat indigestion (Galati et al., 
1994 and Ko et al., 2010), has recently been shown to regulate weight gain and obesity by 
enhancing β-oxidation in vitro and in vivo (Kang et al., 2012). 
 
1.4.3.1 Natural products and AMPK 
Epigallocatechin gallate (EGCG), a constituent from green tea, mediates its anti-obesity 
and glucose regulating effects by activating the 5’ adenosine monophosphate-activated 
protein kinase (AMPK) signaling pathway (Hwang et al., 2007 and Collins et al., 2007). 
Resveratrol, a polyphenolic compound present in red grapes has been shown to be 
effective in preventing CVD, obesity, diabetes and cancer (Jiang, 2008). The benefits of 
resveratrol was found to be associated with increased glucose uptake and decrease 
accumulation of fatty acids through the modulation of AMPK and associated downstream 
proteins involve in glucose signaling and lipid metabolism (Ajmo et al., 2008). 
 
Nelumbo nucifera or “scared lotus” is a Taiwanese flavonoid rich plant which reduces 
fatty acid synthesis and accumulation through the stimulation of AMPK signaling (Wu et 
al. 2010). Ginsenoside, curcumin, coffee acid phenethyl ester (CAPE), berberine and 
theaflavin are a few other natural occurring flavonoid and phenolic compounds which 
were shown to possess anti-obesity, anti-inflammatory, anti-oxidant and anti-tumour 
properties through the modulation of the AMPK signaling pathway (Hwang et al., 2009).  
 
1.5. Adeno monophosphate-activated protein kinase (AMPK) 
The adenosine 5’ monophosphate-activated protein kinase (AMPK) is a serine/threonine 
kinase that plays a central role in energy regulation (Kahn et al., 2005 and Lage et al., 
2008). It is often referred to as the master regulator of energy metabolism controlling 
carbohydrate, lipid and protein metabolism as well as cellular growth and division 
(Carling et al., 2005; Hardie and Sakamoto, 2006). Activation of AMPK in many tissues 
switches off ATP consuming processes while switching on catabolic processes that 
generate ATP. AMPK is activated in response to stresses that deplete cellular ATP 
supplies such as low glucose, hypoxia, ischemia, and heat shock. It exists as a 
heterotrimetric complex composed of a catalytic α subunit and regulatory β and γ subunits 
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(Kahn et al., 2005). Binding of AMP to the γ subunit allosterically activates the complex, 
making it a more attractive substrate for its major upstream AMPK kinase, tumour 
suppressor liver kinase B-1 (LKB-1). Several studies indicate that signaling through 
adiponectin, leptin and calmodulin dependant kinase kinase 2 (CaMKKβ) may also be 
important in activating AMPK (Steinberg and Kemp, 2009). AMPK regulates 
carbohydrate, lipid and protein metabolism, as well as cell growth and apoptosis through 
the regulatory control of key transcriptional factors and enzymes involved in energy 
homeostasis (Figure 3). 
 
 
 
Figure 3. A summary of AMPK function on whole body metabolism.  
Sympathetic nervous system (SNS). (Figure was taken from Khan et al., 2005).  
 
1.5.1 Peripheral AMPK activation  
AMPK is activated by cellular stresses that either interfere with ATP production e.g. 
(hypoxia, glucose deprivation or ischemia) or physiological stresses which increase ATP 
consumption e.g. endurance exercise (muscle contraction) (Kahn et al., 2005). These 
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processes lead to depleting circulating ATP levels and a parallel increase in the AMP: 
ATP ratio, which is believed to be the foremost activator of AMPK and its energy 
regulatory affects (Fogarty and Hardie, 2010). AMPK activation induces energy 
generating catabolic processes such as glycolysis and fatty acid oxidation, improving ATP 
output from glucose and fatty acid utilization (Carling, 2005). At the same time it induces 
the inhibition of energy consuming anabolic pathways such as gluconeogenesis, 
lipogenesis, adipogenesis and protein synthesis, preventing further energy loss (Yang et 
al., 2011). Through processes such as these AMPK reestablishes the ATP:AMP ratio, and 
maintains metabolic energy homeostasis (Steinberg and Kemp, 2009; Fogarty and Hardie, 
2010). 
 
1.5.2 Central AMPK activation  
In addition to AMPK’s role in maintaining cellular energy regulation, it also plays an 
important role in the regulation of whole body energy metabolism (Carling, 2005 and Lim 
et al., 2010). AMPK is ubiquitously expressed in the brain, especially in areas controlling 
food intake and neuroendocrine function such as the hypothalamus and the hindbrain 
(Kola, 2008). AMPK has emerged as a nutrient and glucose sensor in the hypothalamus 
with appetite and energy regulatory effects (Momcilovic et al., 2006). Fasting has been 
shown to result in the activation of AMPK whereas refeeding inhibits AMPK activity in 
multiple hypothalamic regions in mice (López et al., 2008). Hypothalamic activation of 
AMPK has been linked to an increase in food intake and weight gain, whereas its 
inhibition decreases food intake and blunts weight gain. (Andersson et al., 2004 and Kola 
et al., 2008). 
 
The appetite and energy regulatory affects associated with hypothalamic AMPK 
activation has been shown to be controlled by hormones from the gastrointestinal tract 
(peptide YY, ghrelin, cholecystokinin, glucagon-like peptide 1 (GLP-1) and 
oxyntomodulin) and adipokines from adipose tissue (leptin, resistin and adiponectin) 
(Minokoshi et al., 2004; Yang et al., 2011: Steinberg and Kemp, 2009).  
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1.5.3 The AMPK complex 
AMPK is made up of a heterotrimetric complex comprising of a catalytic α subunit and 
two regulatory subunits β and γ (Carling, 2005; Hardie and Sakamoto, 2006). Orthologs 
of the AMPK subunits are found in all eukaryotic species, such as the Snf1 kinase in yeast 
(Amodeo et al., 2007). In mammals each subunit is encoded by multiple genes (α1, α2, 
β1, β2, γ1, γ2, γ3) resulting in numerous isoforms, which generate 12 possible 
combinations of the AMPK protein complex (Amodeo et al., 2007; Hardie and Sakamoto, 
2006).   
 
1.5.3.1 The α subunit 
The α subunit contains a classical serine/threonine protein kinase domain close to the N-
terminal (Lage et al., 2008). When the α subunit forms the heterotrimetric complex with 
the β and γ subunits, the auto-inhibitory function is abolished and its catalytic function is 
attained (Pang et al., 2008). Phosphorylation of the α subunit at Threonine 172 (Thr172) 
by LKB-1 or any other upstream kinases is responsible for the activation of AMPK and its 
energy regulatory effects (Collins et al., 2000; Hawley et al., 2005). 
 
1.5.3.2 The β subunit 
The β subunit serves as a scaffold to the heterotrimetric AMPK complex. This subunit 
contains a specific sequence that binds to glycogen particles, which have been proposed 
to be associated with the tight regulation of glycogen metabolism (Hudson et al., 2003). 
Thus, in addition to its scaffolding function it has an important auto-regulatory function in 
the AMPK complex (Polekhina et al., 2003). 
 
1.5.3.3 The γ subunit 
The γ subunit contains four tandem repeats of the cystothione-β-synthase sequence 
(CBS), located at the N-terminus forming two Bateman domains (Bateman, 1997). The 
Bateman domains selectively bind adenosine containing molecules such as AMP or ATP. 
Binding of AMP to the CBS moieties in the Bateman domains activates AMPK, whereas 
ATP antagonizes this process (Scott et al., 2004). This allosteric interaction increases the 
sensitivity of AMPK to short term changes to intracellular levels of AMP (Suter et al., 
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2006). The unique allosteric regulation between AMP and ATP forms the molecular basis 
for the on and off switch function of AMPK and is a plausible target for synthetic 
activators (Suter et al., 2006; Sanders et al., 2007). 
 
1.5.4 AMPK regulation   
1.5.4.1 The AMP/ATP ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
As previously mentioned, AMPK is activated under stressful conditions which deplete 
ATP stores and increase AMP content in cells (Fogarty and Hardie, 2010). The binding of 
AMP to the CBS domains in the γ subunit induces a conformational change in the 
heterotrimetric complex that promotes the phosphorylation of Thr172 in the α subunit by 
a upstream kinases (Collins et al., 2000; Hawley et al., 2005). In addition to AMP’s 
allosteric regulatory effects on the AMPK structure, it also prevents AMPK’s 
dephosphorylation and inactivation by phosphatase action (Suter et al., 2006; Sanders et 
al., 2007).  
 
1.5.4.2 Liver kinase B-1 (LKB-1) 
The tumour suppressor liver kinase B-1 (LKB-1) which is a serine/threonine kinase has 
been identified as one of the major upstream kinases that phosphorylate Thr172 in the α-
subunit to activate the AMPK (Lizcano et al., 2004). LKB-1 was first identified as a 
tumour suppressor molecule whose inhibition led to an autosomal dominantly inherited 
cancer in humans called the Peutz-Jerghers syndrome (Hemminki et al., 1998; Jenne et 
al., 1998). LKB-1 exists as a heterotrimetric complex with two supporting subunits, the 
mouse protein 25 (MO25) and STE20-related adaptor protein (STRAD) (Hawley et al., 
2003). LKB-1 is said to be constitutively active; its activity is not regulated by stimuli that 
activate AMPK nor is it directly activated by AMP (Hawley et al., 2003). However, as 
previously mentioned the allosteric regulatory effect of AMP on AMPK increases the 
phosphorylating potential of LKB-1 and enhances its phosphorylating function at Thr172 
(Scott et al., 2004). 
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1.5.4.3 Calmodulin dependent kinase kinase β (CaMKK-β) 
Another upstream activator of AMPK has been identified as the calmodulin-dependent 
kinase-kinase-β (CaMKK-β) (Hurley et al., 2005). CaMKK-β phosphorylates AMPK at 
Thr172 independent of cellular ATP levels under the influence of high circulating Ca
2+
 
levels (Hawley et al., 2005). Activation of CaMKK-β by Ca2+ leads to increased fatty acid 
oxidation and glucose utilisation in muscle and liver tissue in an AMPK dependant 
manner (Fogarty and Hardie 2010).  CaMKK-β has been found to be highly expressed in 
the brain, with a depolarisation in K
+
 increasing AMPK activation and its appetite 
regulating effects (Hawley et al., 2005).  
 
1.5.4.4 Transforming growth factor-β-activated kinase 1 (TAK1) 
Transforming growth factor-β-activated kinase 1 (TAK1) is another upstream kinase that 
has been identified to phosphorylate AMPK at Thr172 directly (Momcilovic et al., 2006). 
TAK1 was suggested to be activated by tumour necrosis factor α (TNF α) and 
transforming growth factor β (Srivastava et al., 2007).  
 
1.5.5 Endocrine regulation 
1.5.5.1 Leptin 
Leptin is an adipocyte secreted hormone that plays a crucial role in the regulation of 
feeding, energy expenditure and neuroendocrine homeostasis (Friedman and Halaas, 
1998; Kahn et al., 2005). Leptin acts directly in peripheral tissue to increase fatty acid 
oxidation (Minokoshi et al., 2004) and glucose uptake (Brabant et al., 2005), as well as 
inhibiting fatty acid synthesis in an AMPK dependant manner (Andersson et al., 2004). 
Central nervous system (CNS) leptin stimulated modulation of AMPK has been linked to 
the hypothalamic melanocorticon-sympathetic axis and α-adrenergic signalling in muscle 
(Minokoshi et al., 2002). Hypothalamic activation of leptin seems to inhibit AMPK 
activity, reducing appetite and food intake while increasing peripheral fatty acid oxidation 
through the melanocorticon-sympathetic axis (Minokoshi et al., 2004 and Andersson et 
al., 2004).   
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The development of leptin resistance in obesity has been characterised by suppressed 
rates of leptin stimulated AMPK signalling (Tanaka, 2007). High fat feeding has also 
shown to inhibit leptin’s ability to suppress hypothalamic AMPK signalling (Martin et al., 
2006). 
 
1.5.5.2 Adiponectin  
Adiponectin is an insulin sensitizing adipokine that improves glucose utilisation and fatty 
acid oxidation in muscle and liver, as well as reducing hepatic glucose synthesis 
(Goldstein and Scalia, 2004). Adiponectin stimulates the phosphorylation of AMPK in 
liver and muscle as well as in the CNS (Yamauchi et al., 2002). In contrast to leptin, its 
secretion and plasma concentration is inversely related to adiposity (Lage et al., 2008). 
Plasma adiponectin concentrations are reduced in obese and T2DM individuals (Berg et 
al., 2002). Adiponectin’s over expression has been shown to reverse insulin resistance in 
models of genetic and diet induced obesity (Yamauchi et al., 2002). 
 
1.5.5.3 Ghrelin 
Ghrelin is a gut derived, appetite inducing hormone that has been shown to increase 
AMPK activity in the hypothalamus (Barazzoni et al., 2005; López 2008). Like leptin, 
ghrelin elicits tissue specific effects on AMPK activity (Barazzoni et al., 2005). Ghrelin 
inhibits AMPK activity in the liver (Kola, 2008), while activating AMPK activity in the 
hypothalamus and heart with no effect observed in muscle (Kola, 2008).  
 
1.5.6 AMPK and fuel metabolism 
1.5.6.1 Glucose uptake and utilization 
AMPK plays an important role in glucose metabolism. AMPK activation in response to 
contraction of fast twitching (glycolytic) muscles increases glucose uptake independent of 
insulin (Bergeron et al., 2001 and Fujii et al., 2006). AMPK increases the uptake of 
glucose into the cell by stimulating the expression of hexokinase II and glucose 
transporter 4 (GLUT4), and its enhanced translocation to the cell membrane (Hardie and 
Sakamoto, 2006). Activated AMPK in skeletal muscle phosphorylates and inhibits 
glycogen synthase thus inhibiting glycogen synthesis (Jorgensen at al., 2004). AMPK 
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activity in the liver has been shown to regulate gluconeogenesis by inhibiting the 
transcription of phosphoenolpyruvate-carboxykinase (PEPCK) as well as glucose-6-
phosphatase (Cool et al., 2006).  
   
1.5.6.2 Lipid metabolism and β-oxidation 
AMPK has been shown to play a major role in the regulation of glucose and fatty acids 
through the regulation of key substrates (Kahn et al., 2005). Activated AMPK 
phosphorylates and inhibits acetyl-CoA-carboxylase 1 (ACC1) and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA), decreases fatty acid synthase (FAS) 
expression and activates malonyl-coA CoA carboxylase, leading to decreased fatty acid 
and cholesterol synthesis (López et al., 2008; Lage et a., 2008 and Steinberg and Kemp, 
2009). AMPK stimulates fatty acid oxidation by decreasing malonyl-CoA levels through 
the phosphorylation of ACC2 (Hardie and Sakamoto, 2006). This leads to an increase in 
carnitine palmityol transferase (CPT1, CPT2) activity, facilitating the transport of fatty 
acids such as acetyl-CoA across the mitochondrial membrane and the subsequent 
activation of fatty acid oxidation (Abu-Elheiga et al., 2001; Hardie et al., 2006). AMPK 
has also been shown to stimulate and up regulate the expression of the peroxisomal 
proliferator activated receptors α, γ and β which consequently increases mitochondrial 
biogenesis and the rate of fatty acid oxidation (Jager et al 2007).  
 
Peroxisomal proliferator activated receptor α (PPARα) is predominantly expressed in 
tissues with high rates of mitochondrial and peroxisomal fatty acid metabolism such as 
the liver, heart, brown adipose tissue, skeletal muscle and kidneys (Yoon et al., 2009). 
PPARα functions by regulating the gene expression of key enzymes involved in the 
transport, uptake and oxidation of lipids such as fatty acid transport protein, carnitine 
palmityol transferase-1 (CPT1) and the uncoupling proteins (UCP1, UCP2 and UCP3) 
(Evans et al., 2004 and Yoon et al., 2009). Uncoupling proteins uncouples ATP energy 
and heat from the β-oxidation of circulating free fatty acids decreasing adiposity and 
weight gain (Yonezawa et al., 2009; Schrauwen and Hesselink, 2002). 
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Figure 4. Model for the stimulatory effect of AMPK. 
Stressful conditions such as exercise or hormonal stimuli increase the phosphorylation of 
AMPK, which in turn phosphorylates ACC, inhibiting the conversion of acetyl-CoA to 
malonyl-CoA. This facilitates the transport of long chain acetyl-CoA into the 
mitochondria by CPT1 for fatty acid oxidation in peripheral tissue, including the liver and 
the muscle. (Taken from Khan et al., 2005). 
 
1.6 Cyclopia spp. “Honeybush” 
The Cyclopia spp. is commonly known as “honeybush”.  The Cyclopia genus (Fabaceae 
family, Podalyrieae tribe) consists of 24 species of endemic shrubs which are found in the 
Eastern and Western Cape Floristic regions of South Africa ((Du Toit et al. 1998; Joubert 
et al. 2011). The honeybush plant is easily recognised by its trifoliate leaves, single 
flowered inflorescences and sweetly scented bright yellow flowers (Joubert et al., 2011).  
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Figure 5. Cyclopia maculata.  
Picture of Fabaceae: Cyclopia maculata ‘honeybush’ during the flowering period with 
distinctive, deep yellow flowers which have the characteristic sweet, honey scent. (Picture 
was taken by Marina Joubert, 2010. Genadendal’s hopes for honeybush tea, Science in 
Africa) 
 
Honeybush is consumed as a herbal tea infusion similar to rooibos tea, having a pleasant 
sweet taste and aroma (Joubert et al., 2011). Cyclopia subternata (vleitee), Cyclopia 
intermedia (bergtee) and Cyclopia genistoides (kustee) are a few of the commonly known 
commercial species used for the production of honeybush tea (Joubert et al. 2011). The 
tea is prepared from the leaves and flowers but contain components from the stem as well.  
It is estimated that approximately 50 to 200 tonnes of honeybush is produced in South 
Africa each year (Joubert et al., 2011).  The demand for these teas is growing, partly due 
to their pleasant taste and aroma and partly due to their health promoting properties 
(Joubert et al., 2011).   
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1.6.1 Composition 
Honeybush tea is low in tannins and is caffeine free with a sweet aromatic flavor (Joubert 
et al., 2008). Honeybush contains minerals including Ca
2+
, Cu, Fe, K, Mg, Mn, Na and Zn 
(McKay and Blumberg, 2007). The major phytochemical compounds identified in the 
Cyclopia species have been characterized as the xanthones mangiferin and isomangiferin, 
as well as the flavanone hesperidin (De Nyssenchen et al., 1995 and Joubert et al., 2008; 
2011). In addition to hesperidin, the presence of other flavanones has been demonstrated. 
Honeybush extracts, depending on species, also contain flavones, isoflavones, flavonols, 
coumestans, a benzophenone and a dihydrochalone (Ferreira et al., 1998; Kamara et al., 
2003; Kamara et al., 2004: De Beer et al., 2009 and Kokotkiewicz et al., 2012).  
 
The polyphenolic composition of Cyclopia varies according to species, geographical 
location, harvesting and processing method (Du Toit et al., 1998; De Beer and Joubert, 
2010; Joubert et al., 2011). Fermentation, the oxidation process whereby Cyclopia is 
converted into traditional honeybush tea, reduces the composition and concentration of 
polyphenols (Joubert et al., 2008).   
 
1.6.2 Health benefits 
Honeybush was traditionally prepared as a tea from the leafy shoots and flowers, which 
were dried and fermented to give the sweet honey flavor (Joubert et al., 2008). A 
decoction of C. genistoides was used as restorative and as expectorant in chronic catarrh 
and pulmonary tuberculosis (Bowie, 1980). Cyclopia spp. has been shown to possess anti-
oxidant, anti-cancer and phytoestrogen properties as reviewed by Joubert et al., 2008 and 
2011. In a study by Marnewick et al., 2000, a fermented and unfermented hot water 
extract of honeybush in a dose dependant manner significantly reduced mutagenesis 
induced by 2-acetylaminoflourene (AAF) in vivo in the Salmonella typhimurium strain 
TA198 compared to the control.   
 
In a recent publication by Muller et al., 2011, it was shown that an aqueous extract of 
Cyclopia intermedia was effective in controlling blood sugar levels. Cyclopia has also 
been shown to contain a substance called pinitol, which has been reported to have blood 
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glucose lowering effects in the body (Kim et al., 2007). Mangiferin, a polyphenol 
constituent of honeybush exhibits lipolytic activity (Yoshikawa et al., 2002), and reduces 
the accumulation of triglycerides and intracellular free fatty acids by stimulating AMPK 
activity (Niu et al., 2012). Recent work in our laboratory has provided further evidence of 
the anti-obesity properties of Cyclopia spp. (Dudhia et al., 2013; Patel et al., 2012). 
Dudhia et al. (2013) showed that a fermented, hot water extract of C. maculata inhibits 
adipocyte differentiation in 3T3-L1 adipocytes. Patel et al., 2012, illustrated that C. 
maculata, together with a dietary intervention, ameliorated diet-induced obesity in Wistar 
rats. 
 
1.6.3 Cyclopia maculata 
Cyclopia maculata grows naturally in the Western Cape Province of South Africa 
(Joubert et al., 2011). Cyclopia maculata is not as well studied as other Cyclopia spp. but 
the growing demand for honeybush tea warrants investigation of this species. 
 
High performance liquid chromatography (HPLC) analysis showed that the xanthones 
mangiferin and isomangiferin, as well as the flavanone hesperidin are present in C. 
maculata (Dudhia et al., 2013) as previously reported for other Cyclopia spp. (Joubert et 
al., 2008; 2011). Hesperetin, the aglycone of hesperidin is also present in small amounts 
(Figure 6). 
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Figure 6. HPLC chromatogram of the major phytochemicals in C. maculata.  
(Taken from Dudhia et al., 2013). 
 
1.7 The present study 
A hot water extract of fermented C. maculata has demonstrated anti-obesity properties in 
vitro (Dudhia et al. 2013), and there is evidence of weight regulatory properties in vivo 
(Patel, 2012). The aim of the present study is to determine whether C. maculata treatment 
effected AMPK activation in high fat, high sugar cafeteria diet (CD)-induced obesity in 
Wistar rats. The effect of C. maculata on AMPK activation will be investigated in the 
liver and muscle of lean and obese rats fed a CD.   
 
 
 
 
 
 
 
 
 
Figure 2. The adipocyte life cycle 
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2. Materials and Methods 
2.1 Materials  
Tissue biopsy samples used in this study were obtained from Ms. O. Patel (Patel, 2012). In 
Ms. Patel’s study 21-day old rats (weanlings) were fed a high fat cafeteria diet (CD) for 
12 weeks to induce obesity, with (n=10) or without (n=10) supplementation with a hot 
water extract of fermented 300 mg/kg C. maculata. This was called the lean group. 
Another group of weanlings, the obese group, were fed the CD for 4 months until they 
became obese and thereafter fed the CD for 12 weeks with (n=10) or without (n=10) 300 
mg/kg C. maculata. Rats were terminated after treatment, tissue rapidly excised, and snap 
frozen in liquid nitrogen, whereafter they were stored at -80°C until analysis.  
 
Cyclopia maculata was harvested from a plantation in Riversdale, South Africa and 
fermented by a commercial tea processor (Cape Honeybush Tea Company, Mossel Bay, 
South Africa). A hot water extract of the plant material was prepared by Elizabeth Joubert 
(Infrutec-Nietvoorbij, Agricultural Research Council). The extract and its phenolic 
composition are described in Dudhia et al., 2013. The dose of 300 mg/kg of C. maculata 
extract used was calculated to be equivalent to 5 cups of tea per day (Patel et al., 2012). 
 
The materials used in the study, together with their suppliers, are listed in Appendix A.  
 
2.2 Buffers and solutions 
The recipes of buffers and solutions prepared and used in this study are listed in Appendix 
B.  
 
2.3 Protein extraction 
2.3.1 Cutting and weighing 
Liver and skeletal muscle tissue samples were removed from -80°C and placed in liquid 
nitrogen to prevent thawing. All surfaces and equipment used for weighing were cleaned 
with 70% (v/v) ethanol to prevent contamination. Thereafter, 100 mg of tissue was 
weighed using an analytic balance (Ohaus, UK) and immediately placed on ice to 
preserve sample integrity.  Excess hemoglobin was minimized by briefly rinsing tissue 
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samples with 2 ml of cold phosphate buffered saline, pH 7.5 (PBS) (Sigma-Aldrich, USA) 
for 5 minutes. Thereafter, samples were centrifuged at 15,000 g for 10 minutes at 4°C. 
Supernatants were discarded and 1 ml of in-house lysis buffer was added to the tissue and 
the tissue homogenized with the TissueLyser. 
 
2.3.2 Optimization of protein extraction 
The quality and quantity of proteins are crucial for accurate representation by Western 
blot analysis. Protein extraction from liver and muscle tissue was optimized by comparing 
two different lysis buffers and two different homogenization methods. Three liver and 3 
muscle tissue samples were subjected to protein extraction comparing two lysis buffers, 
an in-house lysis buffer and a commercial lysis buffer (Tissue Extraction Reagent I, 
Invitrogen, USA), and two homogenization methods, the TissueLyser (Qiagen, Germany) 
and the Polytron homogenizer (Brinkmann/Kinematica, Switzerland) (Figure 7).  
 
The in-house lysis buffer (50 mM Tris, 1 mM DTT, 50 mM NaF, 100 µM Na3VO4, 1% 
(v/v) NP40, 1% (v/v) Triton x 114, 25 µg/ml RNase and 1 mM PMSF) and the 
commercial lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 2 mM Na3VO4, 1 
mM NaF, 20 mM Na4P2O7, 0.02% (w/v) NaN3 and proprietary detergent) was 
supplemented with 1x protease and 1x phosphatase inhibitor cocktail tablets (Roche, 
USA). Protease and phosphatase inhibitor cocktail tablets were added to lysis buffer 
according to manufacturer’s instructions; 1 tablet per 10 ml of buffer or as instructed by 
our standard operation procedure for the making of the in-house lysis buffer. Protease and 
phosphatase inhibitor cocktail tablets inhibit a broad spectrum of proteases (serine, 
cysteine and acidic proteases) and phosphatases (acid, alkaline, serine/threonine and 
tyrosine phosphatases).   
 
TissueLyser homogenization works by disrupting biological samples through high-speed 
shaking with beads, which beat and grind samples, releasing the constituents into solution. 
Homogenization was performed by adding a stainless steel bead (Qiagen, Germany) to 
tubes containing tissue samples in lysis buffer. Thereafter tubes were placed in pre-cooled 
adaptors (-80°C overnight) and transferred to the TissueLyser. Tissue samples were 
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homogenized at 25 Hz for 30 seconds followed by one minute incubation on ice. This 
process was repeated four times.  
 
Polytron homogenization was performed at the Department of Medical Physiology, 
Faculty of Health Sciences, Stellenbosch University. Tissue samples and lysis buffer were 
transferred to a round base centrifuge tube on ice. The serrated probe of the Polytron was 
placed into the tube and the tissue ground for 4 seconds at a speed of 4, followed by a 40 
second incubation on ice. The process was repeated four times.  Lysates were clarified by 
centrifugation at 15,000 g for 15 minutes at 4°C.  Supernatants were transferred to 1.5 ml 
tubes and stored at -20°C until protein concentration determination.  
 
 
Figure 7. Experimental layout for optimization of protein extraction.  
Three liver and 3 muscle tissue samples were weighed in quadruplicate and compared 
using two different lysis buffers and two different homogenization methods. 
 
2.4 Acetone precipitation 
Acetone precipitation is a technique used to remove salts and debris from lysate samples 
using solvent based precipitation and high speed centrifugation (Pierce Biotechnology 
Incorporated, 2004). Proteins are insoluble in acetone at low temperatures, whilst many 
small molecules and debris are soluble.   
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Acetone precipitation of samples was performed by adding 3x the volume (3 ml) of cold 
acetone to the lysate, mixed by vortexing and then incubated for 1 hour at -20ºC to allow 
precipitation. The lysate was vortexed briefly for 5 seconds, then centrifuged for 10 
minutes at 13 000 rpm. The supernatant was removed and the protein pellet was air dried 
for 20 minutes. The pellet was dissolved in 300 µl of lysis buffer and mixed by vortexing 
for 10 seconds. Thereafter, the pellet was homogenized in the TissueLyser for 1 minute at 
25 Hz and left on ice for 10 minutes. The lysate was centrifuged for 5 minutes at 13 000 
rpm whereafter the supernatant was transferred to a fresh tube and freezed at -20ºC. 
 
2.5 Protein concentration determination 
Protein concentrations were quantified using the RC DC kit (BioRad, USA). The RC DC 
assay is based on the Lowry method of protein estimation, where proteins react with 
alkaline copper and subsequently reduces folin reagent, resulting in color development. 
The RC DC assay is a protein concentration determination kit which is compatible with 
samples containing reducing agents and detergents, the major interfering agents in protein 
estimation. 
 
A standard curve was prepared using bovine serum albumin (BSA) (BioRad, USA) (Table 
1). To ensure that the absorbance of unknowns fell within the range of the standard curve, 
it was decided to dilute protein samples 1:20. Proteins were diluted by adding 1 µl of 
sample to 19 µl of lysis buffer. To minimize interference from lysis buffer constituents, 
lysis buffer for absorbance readings was diluted 1:2 with double distilled water (ddH2O) 
(500 µl of lysis buffer and 500 µl of ddH2O) and used at a half strength concentration. 
Five microliters of BSA standards and protein samples were added to separate wells of a 
96 well microtiter plate (Sigma-Aldrich, USA) in duplicate (Figure 8). Twenty five 
microliters of solution A’ was added to each well followed by 200 µl of reagent B. 
Solution A’ was made by mixing 20 µl of reagent S and 1 ml of reagent A. Thereafter, the 
plate was mixed on a plate mixer (Scilogex, USA) for 10 seconds. Plates were left at 
room temperature for 15 minutes whereafter absorbance was measured at 630 nm using a 
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†
A stock solution of 1.44 µg/µl BSA was used 
 
spectrophotometer (BioTek, USA). Data was exported to Excel (Microsoft Office, 
Version 2003, USA) for analysis. 
 
 
Table 1. Preparation of the BSA standard curve 
 
[BSA] 
µg/µl 
Volume (µl) 
BSA  Lysis buffer Total 
1.44† 20 0 20 
1 13.8 6.2 20 
0.5 7 13 20 
0.2 2.8 17.2 20 
0 0 20 20 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0           
B 0.2 0.2           
C 0.5 0.5           
D 1 1           
E 1.44 1.44           
F             
G             
H             
 
Figure 8. Representative 96 well microtiter plate layout for protein determination.  
BSA standards were pipetted in duplicate into wells shaded in blue. Unknown samples 
were pipetted, in duplicate, in the remainder of the plate. To avoid inaccuracies, the 
concentrations of no more than 20 unknowns were analyzed per plate.  
 
2.6 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their size. SDS is an anionic detergent that binds 
quantitatively to proteins, denaturing their tertiary structure, and linearizing them 
(Westermeier, 2000). The polyacrylamide gel is a cross-linked matrix which allows 
proteins, which are negatively charged due to their binding with SDS, to migrate towards 
the anode when an electric current is passed through the gel.  
 
Proteins were separated by SDS-PAGE to assess the quality of the extracted proteins, or 
for Western blot analysis. For the assessment of protein quality, 10 µg of protein was 
separated by SDS-PAGE and thereafter subjected to Coomassie blue staining for protein 
visualization. For Western blot analysis, 60 µg of protein was subjected to electrophoretic 
separation and thereafter transferred to polyvinylidene fluoride (PVDF) membranes. 
Proteins were separated using a 4% stacking gel over a 10% resolving gel.  
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One millimetre spacer plates (BioRad, USA) and cover plates (BioRad, USA) were 
cleaned with dish washing liquid, rinsed with water then wiped with 70% (v/v) ethanol 
and paper towel. Plates were assembled on assembling racks (BioRad, USA). The 
resolving gel was poured into plates until it reached 2 cm from the top of the plate, 
overlaid with water saturated butanol and left to set at room temperature for 30 to 40 
minutes. Water saturated butanol was discarded, gels were rinsed with distilled water and 
blotted with Whatmann paper to get rid of excess water. Thereafter, the stacking gel was 
overlaid onto the resolving gel; the well combs were inserted and the gel was allowed to 
set at room temperature for 30 to 40 minutes.  
 
Protein samples were prepared by diluting all samples to the concentration of the most 
dilute sample. This ensured that the same volume of sample was loaded onto the SDS-
PAGE gel.  Thereafter, an equal volume of 2x Leammli sample loading buffer (BioRad, 
USA) was added. Proteins were divided into 100 µl aliquots and stored at -20°C or used 
immediately. Double the volume of sample corresponding to 10 or 60 µg of protein was 
transferred to a new tube, and proteins were denatured by heating at 95°C on a heat block 
(Labnet, USA) for 5 minutes. A double volume was heated at 95˚C in case of protein loss 
during denaturation, and to ensure that a total of 10 or 60 µg of protein was added to gels. 
Thereafter, tubes were briefly spun down for a few seconds and placed on ice.  
 
Glass plates containing the set gels were placed into an electrophoresis chamber (BioRad, 
USA) and half filled with 1x SDS-PAGE running buffer (25 M Tris, 1.9 mM Glycine, 1% 
SDS). Protein samples were loaded onto gels, tanks were filled with running buffer, and 
gels were run at 150 V for 70 minutes using the Mini-Protean Tetra Electrophoresis 
system (BioRad, USA). For protein visualisation with Coomassie blue, 10 µl of the 
unstained protein ladder (Pierce, USA) was used as molecular weight marker. For 
Western blot analysis, 10 µl of the prestained protein ladder and 5 µl of the Cruz Marker 
(Santa Cruz, USA) were used as molecular weight markers. The prestained Fermentes 
protein ladder (Thermo Scientific, USA) was used as a molecular weight marker to 
visualise the transfer of proteins to the PVDF membrane (Millipore, USA) and the Cruz 
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marker, was used as a chemiluminescent molecular weight marker, to asses sizes after 
Western blot analysis.  
 
After electrophoresis, gels were removed and stained with Coomassie blue or transferred 
to PVDF membranes for Western blotting.  
 
2.7 Coomassie blue staining 
Forty millilitre of Coomassie blue stain (BioRad, USA) was added to gels and incubated 
at room temperature for 16 to 18 hours shaking. Gels were destained with 10% (v/v) 
acetic acid and 30% (v/v) methanol 3 washes, 2x 3 hours and 1x for 16 hours until protein 
bands became visible. Gel images were captured using the BioRad, USA ChemiDoc
TM
 
XRS
+ 
image illuminator and Quantity One software.  
 
The camera, ChemiDoc system and the computer were switched on a few minutes in 
advance before use. The Quantity One software programme was opened and the 
ChemiDoc XRS file selected to open the acquisition window. The UV plate converter was 
placed on the glass plate in the imager. An A4 sheet containing a hole the size of the gel 
was placed on the UV plate converter to orient the gel. A piece of paper, with a black 
cross, was cut to the same size as the gel and was placed in the hole to facilitate focusing. 
The Trans UV option on the imager and the UV Trans option in the acquisition window 
were selected and the image oriented and focused. The live/focus option was selected; the 
iris was closed until the cross on the paper came into focus and adjusted with the near/far 
or wide/narrow options. The piece of paper was removed and the Coomassie stained gel 
was placed on UV plate converter. The gel image was viewed through live/focus, freezed, 
then captured using the auto exposure option and saved. 
 
2.8 Western blot analysis 
Western blot analysis is a method used to identify and quantify specific proteins of 
interest. Proteins are separated according to their size using SDS-PAGE and thereafter 
transferred to a membrane, usually nitrocellulose or PVDF membranes, using an electrical 
current. Membranes are incubated with a primary antibody to detect the protein of 
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interest, followed by incubation with a secondary antibody coupled to horse radish 
peroxidase (HRP) to facilitate detection. Addition of a chemiluminescent substrate allows 
visualisation of proteins of interest. The detection signal is directly proportional to the 
concentration of the protein on the membrane.   
 
2.8.1 Transfer  
After SDS-PAGE electrophoresis, proteins were transferred to PVDF membranes using 
the Mini Trans-Blot Cell system (BioRad, USA). PVDF (Millipore, USA) membranes 
and Whatman paper (Whatman Ltd, UK) were cut according to the size of gel. The 
membrane was activated by gently shaking in 100% (v/v) methanol for 1 minute followed 
by 5 minutes in distilled water. Membranes, fibre pads, Whatman paper and gels were 
equilibrated by gently shaking in transfer buffer (25 mM Tris, 192 mM Glycine, 20% 
(v/v) methanol) for 20 minutes. The transfer sandwich was assembled by opening the 
transfer cassette, placing the black negative side face down in a container with transfer 
buffer, followed by the fibre pad, Whatman paper, gel, PVDF membrane, Whatman 
paper, fibre pad and then closed with the white positive side of the cassette. A roller bar 
was rolled over the transfer sandwich at each step to ensure that no air bubbles were 
trapped in the sandwich. Air bubbles hinder the transfer of proteins from the gel to the 
PVDF membrane.  
 
Figure 9. Diagrammatic illustration of Western blot transfer sandwich. 
PVDF membrane 
Gel 
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Transfer cassettes were placed between the electrodes of the Mini Trans-Blot Cell system 
according to manufacturer’s instructions, black to black and red to red. An ice pack frozen 
at -20˚C was placed next to the black side of sandwich and a magnetic stirrer bar was 
added to the electrophoresis unit. The ice pack is used to ensure that the transfer system 
does not heat up due to the high voltage of electricity used, as well as to prevent 
degradation of proteins being transferred. The unit was filled with transfer buffer and 
placed on a magnetic stirrer (Sigma-Aldrich, USA). Proteins were allowed to transfer at 
30-40 V overnight or at 160 V for 2 hours at room temperature.  
 
After transfer, the cassette was disassembled and the protein side of the PVDF membrane 
was marked with a pencil. The membrane was stained with Ponceau stain (Sigma-
Aldrich, USA) for five minutes then rinsed with distilled water to destain. Images were 
captured using the Bio-Rad ChemiDoc
TM
 XRS
+ 
image illuminator and Quantity One 
software. Imaging was performed as described in section 2.6, with the exception that the 
White Epi illumination options was selected on the scanner and in the acquisition 
window. The UV plate converter was also removed from the imager. The iris of imager 
camera was closed by using the open/close function in the acquisition window. The 
Ponceau stained blot was viewed through live/focus, freezed, then captured using the auto 
exposure option and saved. After imaging, membranes were washed with 1x Tris-buffered 
saline, pH 7.6 containing 0.2% (v/v) Tween-20 (TBST) until the Ponceau stain was 
removed. Ponceau stain is a rapid reversible protein staining method and does not have 
any deleterious effects on subsequent steps (Sigma-Aldrich, USA). 
 
2.8.2 Blocking 
PVDF membranes were blocked with 5% (w/v) non-fat milk powder (Elite Clover, SA) in 
TBST for 7 hours. Blocking of membranes is essential to prevent the non-specific binding 
of the detection antibody to other proteins or binding sites.  
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2.8.3 Primary antibody 
After blocking the membrane, antibodies specific to the protein of interest were added to 
the membrane. The antibodies used in the study are indicated in Table 2. Antibodies were 
diluted in TBST according to the manufacturer’s instructions. Membranes were placed in 
50 ml skirted tubes and the antibody solution overlaid in the section of the membrane 
where the antibody of interest is expected to bind. Tubes were positioned on a shaker 
(Stuart, UK) in a cold room at 4ºC overnight for 16 to 17 hours. 
 
Table 2. Primary antibodies used in study  
Antibody Source Type  Dilution 
pAMPK Rabbit mAb† 1:500 
AMPK Rabbit pAb‡ 1:1000 
ACC Rabbit mAb† 1:1000 
UCP2 Goat mAb† 1:2500 
PPAR Rabbit mAb† 1:1000 
PRARα Rabbit pAb‡ 1:1000 
β-tubulin Rabbit pAb‡ 1:1000 
β-actin Mouse mAb† 1:250 
†Monoclonal antibody, produced in a single B-lymphocyte generating antibodies to one specific 
epitope on antigen 
‡Polyclonal antibody, produced by multiple B-lymphocytes generating antibodies to target 
various epitopes on antigen 
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2.8.4 Secondary antibody 
The following day, membranes were washed with TBST for 3x 15 seconds, then 1x 15 
minutes and again for 3x 5 minutes. After washing, membranes were incubated with host 
specific secondary antibody (Table 3), in 2.5% (w/v) non-fat milk powder in TBST for 90 
minutes at room temperature with shaking on a belly dancer (StoVoll, USA).  
 
Table 3. Secondary antibodies used in study 
Antibody Source Dilution 
Mouse HRP IgG Donkey 1:4000 
Rabbit HRP IgG Donkey 1:4000 
Goat HRP IgG Donkey 1:4000 
Secondary antibodies, specific to the primary antibodies used, were labelled with 
horseradish peroxidase to facilitate detection.  
 
2.8.5 Protein detection 
Membranes were washed as described previously, and incubated with LumiGLO 
Chemiluminescent Substrate Kit (KPL, USA) for 1 minute. LumiGlo chemiluminescent 
solution was prepared an hour in advance as to the manufacturer’s instructions, by mixing 
one part solution A (luminal solution) with two parts solution B (reaction buffer) and left 
at room temperature for 1 hour to acclimatise. Proteins of interest were then detected with 
the Bio-Rad ChemiDoc
TM
 XRS
+ 
image illuminator and Quantity One software.  
 
Imaging was performed as described in section 2.6, with the exception that the Epi-White 
switch on the imager and the Chemi Hi Sensitivity option in the acquisition window of the 
software was selected. The iris of the camera was completely opened until the black cross 
on the paper disappeared and the BioRad logo with lanes on the ruler became visible 
through live/focus. The camera lens was focused near/far or wide/narrow to obtain a clear 
image of BioRad logo and the lanes on the ruler. The piece of paper and ruler was then 
removed and the blot placed in the centre of A4 sheet on the glass plate. The blot was 
brought into focus and the Epi-White switched off on the imager. The live acquire option 
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was selected with a total exposure time of 1 to 2 minutes with 10 sec intervals. Images 
acquired were saved for quantification and analysis.  
 
2.8.6 Quantification 
Quantification of Western blot images was done using the Quantity One software 
(BioRad, USA). The Quantity One software programme was opened on the computer 
desktop. The saved western blot image e.g. pAMPK was opened. The image of the blot 
was then aligned and cropped to view distinctive linear, protein bands using the crop 
function in the image tools bar. Protein bands of interest were encircled using the 
rectangular action tool in the volume tools bar. An empty space on the blot where no 
protein binding was present was also encircled with the rectangular volumes tool. The 
empty space was used as a blank to subtract non-specific background binding from the 
blot image for quantification of protein bands. The volume report option was then 
selected in the volumes tools bar for the volume density analysis. Results from the volume 
density report were exported to Microsoft Excel 2003, for further analysis. The total 
expression of the protein of interest was determined by dividing its band volume density 
with that of a house keeping protein, β tubulin or β actin.  A house keeping protein is 
expressed at constant levels and is not usually affected by the treatment or experiment. 
 
2.8.7 Stripping 
To allow for reprobing of membranes with another protein of interest, PVDF membranes 
were stripped with 10 ml of stripping buffer (Thermo Scientific, USA) to remove primary 
and secondary antibody. Stripping buffer was incubated for 15 minutes, the solution 
decanted and the membrane gently washed in TBST and stored at 4°C. To assess the 
efficiency of stripping, stripped membranes were incubated with LumiGLO 
Chemiluminescent Substrate Kit as described previously. This was only done with the 
first stripping procedure.  
 
2.9 Enzyme-linked immunosorbent assay 
The AMPKα [pT172] kit from Invitrogen (Life technologies, USA) is a solid phase 
sandwich enzyme-linked immunosorbent assay (ELISA). A monoclonal antibody specific 
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to AMPKα (regardless of its phosphorylation state) has been coated on a microtiter strip. 
The coated antibody binds to AMPKα protein in tissue lysates, trapping it to the 
microtiter strip. The addition of an antibody directed at AMPKα phosphorylated at 
Thr172 binds to the immobilized AMPKα protein if phosphorylated. Addition of an anti-
rabbit IgG HRP antibody which binds to the detection antibody completes the four 
member sandwich as illustrated in Figure 10. Addition of the Tetramethylbenzidine 
(TMB) substrate will then result in an enzymatic color reaction whose intensity is directly 
proportional to the concentration of AMPKα phosphorylated at Thr 172 in the sample. 
 
 
 
Figure 10. Illustration of the AMPK [pAMPK-T172] double sandwich ELISA. 
The capture antibody which is attached to the microtiter plate binds the target protein 
during incubation with the tissue lysate. Addition of a target specific detection antibody 
binds to the stationary captured target protein. An HRP-linked antibody is then added to 
bind and detect the detection antibody. Addition of the TMB substrate results in an 
enzymatic color reaction which may be detected using a spectrophotometer at a 
wavelength of 450 nm.   
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2.9.1 Acclimatization of reagents and solutions 
All reagents and buffers were allowed to reach room temperature before use, and 
thereafter gently mixed. All ELISA reagents are listed in appendix A and the recipes of 
solutions used listed in appendix B. The desired number of 8 well strips to be used was 
allowed to reach room temperature and the rest of the strips resealed and stored until 
required. 
 
2.9.2 Incubation with standards and protein lysate 
One hundred microliters of standard diluent buffer was added to the wells to be used, 
leaving the wells reserved for the chromogenic blank empty as illustrated in Figure 11. 
One hundred microliters of standards, controls and diluted samples were added to the 
appropriate microtiter plate wells as illustrated in Figure 11 and mixed by gently tapping 
the side of plate. Wells were covered with a plate cover and incubated for 2 hours at room 
temperature at 25ºC.  The solution in the microtiter wells was decanted and discarded 
after incubation. Wells were washed 4 times by flooding with washing solution using a 
squirt bottle. Thereafter, solutions were decanted and the plate inverted on absorbent 
tissue to dry.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 U1 U1 U9 U9 U11 U11      
B 50 U2 U2 U10 U10 U12 U12      
C 25 U3 U3 U19 U19 U13 U13      
D 12.5 U4 U4 U20 U20 U14 U14      
E 6.25 U5 U5   U15 U15      
F 3.16 U6 U6   U16 U16      
G 1.6 U7 U7   U17 U17      
H 0 U8 U8 CB CB U18 U18      
 
Figure 11. Representative 96 well microtiter plate layout for ELISA.  
Unknown (U), Chromogenic Blank (CB). 
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AMPKα standards were pipetted into the wells shaded in dark blue (100 U/ml, 50 U/ml, 
25 U/ml, 12.5 U/ml, 6.25 U/ml, 3.16 U/ml, and 1.6 U/ml). The chromogenic blank (CB) 
was pipetted into wells H4 and H5. To avoid inaccuracies, no more than 20 unknowns 
(e.g. U1) (Lanes 2-7) was analyzed in duplicate per assay. 
 
2.9.3 Incubation with detection antibody 
One hundred microliters of AMPKα [pT172] detection antibody solution was added to 
each well except for the chromogenic blank well then gently mixed by tapping the side of 
the plate. The microtiter plate was covered with the plate cover and incubated for 1 hour 
at room temperature. The solution in the wells was discarded after incubation and the 
wells were washed 4 times as previously described.  
 
2.9.4 Incubation with HRP anti-rabbit antibody 
One hundred microliters of the anti-rabbit IgG HRP working solution was added to each 
well except for the chromogenic blank wells, and gently mixed by tapping the side of the 
plate. The microtiter plate was covered with a plate cover and incubated for 30 minutes at 
room temperature. The solution in the microtiter well strips was discarded after incubation 
and the wells were washed 4 times as described previously.  
 
2.9.5 Incubation with stabilized chromogenic solution 
One hundred microliters of stabilized chromogenic solution was added to each well 
including the chromogenic blank wells, and gently mixed by tapping the side of the plate. 
The microtiter plate was covered with a plate cover and incubated for 30 minutes at room 
temperature.   
 
2.9.6 Incubation with stop solution and detection at 450 nm 
One hundred microliters of stop solution was added to each well and gently mixed by 
tapping the side of the plate. The color of the solution in the wells changed from blue to 
yellow. The absorbance of each well was read 30 minutes after the addition of the stop 
solution at 450 nm using a spectrophotometer (BioTek, USA). Data was exported to Excel 
(Microsoft Office, Version 2003) for analysis. 
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2.9.7 Quantification 
A standard curve was plotted using the known pAMPK standards (x axis) against their 
corresponding optical density readings (y axis) in Microsoft Excel using the scatter plot 
diagram option. Phosphorylated AMPK expression in samples were determined by 
solving for x using the linear regression equation (y=mx+c) provided with the standard 
curve in Excel.  
 
2.10 Histological analysis of retroperitoneal fat pads 
Histology is the study of the microscopic anatomy of cells and tissues of plants and 
animals. It entails the sectioning of tissue biopsies, their staining and observational 
analysis by microscopy. Haematoxylin and eosin is the most commonly used stains, 
providing contrast to tissues for visualisation as well as highlighting particular features of 
interest. Haematoxylin is a cationic or basophilic dye binding to negatively charged tissue 
ions such as chromatin in the nucleus. Eosin is an anionic or acidophilic dye binding to 
positively charge tissue ions such as the amino groups of proteins, cytoplasm. Adipocytes 
appear as translucent vacuoles surrounded by a thin cytoplasmic rims when H&E stained 
(Figure 12). 
 
 
Figure 12. Representative picture of H&E straining of retroperitoneal fat.  
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Histology of retroperitoneal fat (RF) pads was done to determine the effect of C. maculata 
on adipocyte size and number. Retroperitoneal fat is an important visceral fat depot store. 
The retroperitoneal fat depot is sensitive to the storage and release of fatty acids, thereby 
influencing their morphology and cell number (Bjørndal et al., 2011). 
 
2.10.1 Slide preparation and dewaxing 
Retroperitoneal fat biopsies from Wistar rats (Patel, 2012) were fixed in 4% (v/v) 
buffered formalin and embedded and preserved in paraffin wax blocks. Tissue was 
dissected into 1 millimeter sections and wet mounted onto glass slides. Slides were placed 
on slide racks and incubated at 60˚C for approximately 30 minutes or until most of the 
wax surrounding the sections had melted away. The tissue sections on the slides were de-
waxed by placing in xylene (Merck, USA) for 10 minutes, then placed in a second 
container with xylene for another 10 minutes.  The tissue was hydrated by placing in 95% 
(v/v) ethanol twice for 2 minutes followed by rinsing by 20 dips in water. 
 
2.10.2 Haematoxylin staining 
The slides were stained in Haematoxylin solution for 12 minutes, followed by a 10 dip 
wash in water. The slides were then immersed in a container with running tap water to 
induce “Bluing” of the stained tissue sections. Bluing is the process of converting the 
initially red soluble hemalum to a final insoluble blue form. Slides were then rinsed by a 
10 dip wash in water. 
 
2.10.3 Eosin staining 
The slides were stained in 1% (w/v) Eosin solution for 5 minutes, followed by a 10 dip 
wash in water. The slides were hydrated by dipping 20 times in 95% (v/v) ethanol, 
followed by another 20 dips in 100% (v/v) ethanol.  
 
2.10.4 Mounting of cover slip 
Slides were dipped 20 times in xylene and then left in xylene for mounting of the cover 
slip. Mounting was done by adding one drop of Entallen (Merck, Germany) onto the slide 
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followed by the cover slip. Mounting preserves the integrity of the stained tissue as well 
as making it transparent, making examination of the slides easier. 
 
2.10.5 Image capturing and analysis 
Images of slides were captured with x20 magnification and 10 fields per section were 
captured using an Olympus BX50 light microscope (Olympus, Japan) interfaced with 
NIS-Element BR 3.0 software (Nikon instruments Inc, USA). 
 
2.10.6 Quantification of images 
The adipocyte sizes were measured with the Leica Qwin pro version 3 (Leica 
Microsystems, Germany) image analysis software program.  The adipocyte cell sizes were 
expressed as mean arbitrary units per 10 fields.  The Grubb’s test (Graphpad Prism, USA) 
was used to detect outliers (http://graphpad.com/quickcalcs/grubbs2.cfm). 
 
2.11 Statistical analysis 
Data analysis was performed in Microsoft Excel (Microsoft Office version 2010, USA). 
Results are expressed as the mean ± standard error of the mean (SEM). The SEM was 
calculated by dividing the standard deviation (calculated by Microsoft Excel) by the 
square root of the number of samples analyzed. Statistical analysis was performed using 
GraphPad Prism (Version 5.01, USA). The two-tailed unpaired t-tests, corrected for by 
the Welch’s correction, was used to compare two groups, while the one way analysis of 
variance (ANOVA) with a Tukey post doc test was performed to determine any statistical 
significant variation between groups.  A p-value of <0.05 was considered statistically 
significant.   
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Chapter 3 
 
 
 
Results 
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3. Results 
3.1 Protein extraction  
3.1.1 Optimization 
SDS-PAGE of proteins extracted using the in-house lysis buffer and the TissueLyser 
showed smearing, suggesting protein degradation, contamination with cellular debris and 
salts, incorrect pH of buffers or incorrect gel pouring (Figure 13).  To improve the purity 
of protein lysates, acetone precipitation, a technique that is used to remove chemicals and 
salts from protein samples (Rinderknecht et al., 1939), was conducted. At low 
temperatures, proteins are insoluble in acetone while other chemicals and salts are soluble 
and precipitate out of lysates after high speed centrifugation (Rinderknecht et al., 1939). 
Our results showed that although acetone precipitation improved protein quality, a loss of 
high and low molecular weight proteins was observed (Figure 14). In an attempt to 
improve protein quality without affecting protein yield, protein extraction was compared 
using two different lysis buffers (in-house buffer vs. commercial buffer) and two different 
homogenization methods (TissueLyser vs. Polytron). 
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Figure 13. SDS PAGE of proteins before optimization.  
Proteins were extracted from the liver of lean (A, lanes 2-10) and obese (B, lanes 1-9) 
rats using the in-house lysis buffer and the TissueLyser. Thereafter 10 µg of protein was 
separated by 10% SDS PAGE. The prestained protein ladder is indicated in lane 1 (A). 
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Figure 14 SDS PAGE of proteins after acetone precipitation.  
Proteins were extracted from the liver of lean (A, lanes 1-10) and obese (B, lanes 1-
10) rats using the in-house lysis buffer and the TissueLyser. Thereafter proteins were 
purified by acetone precipitation and 10 µg of protein was separated by 10% SDS 
PAGE.  
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3.1.1.1 Protein concentration  
Protein concentrations were determined using the RC DC kit. As illustrated in Figure 15, 
high correlation coefficients (R
2
) were obtained when using the in-house (0.996) and the 
commercial (0.994) lysis buffer as BSA diluents, thus supporting the use of these curves 
for protein concentration determination using the linear equation:  
y=mx + c  
y=absorbance, m=gradient, x=concentration and c=y-intercept. 
 
 
 
 
 
B 
A 
 
Figure 15. BSA standard curves.  
Standard curves were prepared using the in-house (A) or commercial (B) lysis buffers as BSA 
diluents. Absorbance values were determined using the RC DC kit. 
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3.1.1.2 Protein yield 
The total yield of proteins extracted using the two different extraction procedures was 
calculated. Protein yield varied according to tissue type, lysis buffer and homogenization 
method (Table 4, Figure 16).  
 
The yield of proteins extracted from liver samples using the commercial lysis buffer was 
increased compared to the in-house lysis buffer, irrespective of homogenization method 
used (Polytron 44.60 ± 4.60 vs. 28.41 ± 6.02 (1.6-fold (p=0.0208)); TissueLyser 69.36 ± 
10.83 vs. 36.48 ± 6.89 (1.9-fold (p=0.0114)).  
 
For muscle samples, no significant differences in protein yield was observed when 
comparing the two different lysis buffers and the two homogenization methods (Table 4, 
Figure 16). Even though similar tissue weights used for protein extraction (100 mg), the 
protein yield of muscle samples were significantly lower than that of liver samples when 
comparing the same protein extraction procedures (commercial lysis buffer and Polytron 
10.98 ± 0.98 vs. 44.60 ± 4.60 (4.1-fold (p=0.0002)); commercial lysis buffer and 
TissueLyser 11.27 ± 1.19 vs. 69.36±10.83 (6.2-fold (p=0.0008)); in-house lysis buffer and 
Polytron 11.64 ± 3.68 vs. 28.41±6.02 (3.2-fold (p=0.0146); in-house lysis buffer and 
TissueLyser 8.80 ± 1.16 vs. 36.48 ± 6.89 (4.2 fold (p=0.0024)). 
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Table 4. Protein concentration and yield after optimization.   
 
Tissue 
Lysis 
buffer Homogenization Sample No 
Concentration 
(mg/ml) 
Total Yield
 
(mg) 
Liver 
Commercial 
Polytron 
D71 1 61.64 49.31 
B51 2 50.15 40.12 
B53 3 55.47 44.38 
Average  55.75 44.60 ± 4.60*
###
 
TissueLyser 
D71 4 81.74 65.39 
B51 5 102.01 81.61 
B53 6 76.33 61.07 
Average  86.69 69.36± 10.83
ǂ$$$
 
In-house 
Polytron 
D71 7 42.36 33.89 
B51 8 36.73 29.38 
B53 9 27.45 21.96 
Average  36.45  28.41 ± 6.02*
ѱ
 
TissueLyser 
D71 10 36.45 29.16 
B51 11 53.55 42.84 
B53 12 46.82 37.45 
Average  45.61  36.48 ± 6.89
ǂ††
 
Muscle 
Commercial 
Polytron 
D71 13 15.02 12.01 
B51 14 12.57 10.05 
B53 15 13.58 10.86 
Average  13.72 10.98 ± 0.98
###
 
TissueLyser 
D71 16 15.78 12.62 
B51 17 13.50 10.80 
B53 18 12.99 10.39 
Average  14.09 11.27 ± 1.19
$$$
 
In-house Polytron 
D71 19 12.45 9.96 
B51 20 19.82 15.85 
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B53 21 11.36 9.09 
Average  14.55 11.64 ± 3.68
ѱ
 
TissueLyser 
D71 22 11.00 8.80 
B51 23 9.55 7.64 
B53 24 12.45 9.96 
Average  11.00 8.80 ± 1.16
††
 
Proteins were extracted from liver and muscle samples using the commercial or in-house 
lysis buffers and the Polytron or TissueLyser. Concentrations were determined using the 
RC DC kit and protein yield was calculated by multiplying the concentration obtained by 
the final volume. Results are expressed as the mean ± standard error of mean.  
*Commercial lysis buffer and Polytron vs. In-house lysis buffer and Polytron 
ǂCommercial lysis buffer and TissueLyser vs. In-house lysis buffer and TissueLyser 
#
Commercial lysis buffer and Polytron:  liver vs. muscle 
$
Commercial lysis buffer and TissueLyser:  liver vs. muscle 
Ѱ
In-house lysis buffer and Polytron:  liver vs. muscle 
†
In-house lysis buffer and TissueLyser:  liver vs. muscle 
*
ǂѱ
P value < 0.05, 
††
P value < 0.01, 
###,$$$
P value < 0.001. 
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Figure 16. Graphical representation of protein yield after optimization.  
Proteins were extracted from liver (A) and muscle (B) tissue using two different lysis 
buffers (in-house vs. commercial) and  two different homogenization methods (Polytron 
vs. TissueLyser). Protein yield was determined by multiplying the concentrations 
obtained by the total volume.  Results are expressed as the mean ± standard error of 
mean. * p < 0.05. 
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3.1.1.3 Protein profiling 
To visually examine the quality of the proteins extracted using the different optimization 
conditions, 10 µg or 60 µg of protein was separated by 10% SDS-PAGE (Table 5 and 6 
respectively), stained with Coomassie blue and visualized with the ChemiDoc illuminator. 
A low (10 µg) and a high (60 µg) concentration of protein was used to investigate whether 
protein amount affected banding patterns. No difference in protein profiles were observed 
in liver samples, irrespective of the lysis buffer or homogenization method used and the 
amount loaded (Figures 17 and 19).  Muscle proteins that were extracted using the 
commercial lysis buffer, regardless of whether the Polytron or TissueLyser was used, 
displayed more low and high molecular weight protein bands compared to proteins 
extracted using the in-house lysis buffer (Figures 18 and 20).  
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Table 5. Volumes of proteins (10 µg) for SDS-PAGE profiling. 
 
Sample 
No. 
Protein 
concentration 
Volume
†
 
used (µl) 
Volume
† 
water (µl) 
2x Sample 
buffer (µl) 
Volume for 
gel
‡ 
(µl) 
Tissue 
type 
1 61.64 1 9 10 3.2 liver 
2 50.15 1 9 10 4.0 liver 
3 55.47 1 9 10 3.6 liver 
4 81.74 1 9 10 2.4 liver 
5 102.01 1 9 10 2.0 liver 
6 76.33 1 9 10 2.6 liver 
7 42.36 1 9 10 4.7 liver 
8 36.73 1 9 10 5.4 liver 
9 27.45 1 9 10 7.3 liver 
10 36.45 1 9 10 5.5 liver 
11 53.55 1 9 10 3.7 liver 
12 46.82 1 9 10 4.3 liver 
13 15.02 1 9 10 13.3 muscle 
14 15.78 1 9 10 15.9 muscle 
15 13.50 1 9 10 14.7 muscle 
16 12.99 1 9 10 12.7 muscle 
17 15.78 1 9 10 14.8 muscle 
18 13.50 1 9 10 15.4 muscle 
19 12.45 1 9 10 16.1 muscle 
20 11.00 1 9 10 10.1 muscle 
21 9.55 1 9 10 17.6 muscle 
22 12.45 1 9 10 18.2 muscle 
23 11.00 1 9 10 21.0 muscle 
24 9.55 1 9 10 16.1 muscle 
 
 
†
Protein samples were diluted 1:10 to facilitate loading onto the gel.  
‡
A volume equal to 10 µg of protein and an equal volume of 2x sample buffer was loaded 
onto gels. 
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†
120 µg of protein was used to prepare the mixture for loading in case of 
protein loss during pipetting 
‡ The half (60 µg) was loaded onto the gel.  
Table 6. Volumes of proteins (60 µg) for SDS-PAGE profiling. 
 
Sample 
No. 
Starting 
concentration 
(µg/µl) 
For 120 µg
† 
(µl) 
2x Sample 
buffer 
(µl) 
Volume (60 
µg)for  gel
‡
 
(µl) 
Tissue 
type 
1 61.64 1.9 1.9 1.9 liver 
2 50.15 2.4 2.4 2.3 liver 
3 55.47 2.1 2.1 2.1 liver 
4 81.74 1.4 1.4 1.4 liver 
5 102.01 1.2 1.2 1.2 liver 
6 76.33 1.5 1.5 1.5 liver 
7 42.36 2.8 2.8 2.8 liver 
8 36.73 3.2 3.2 3.2 liver 
9 27.45 4.3 4.3 4.3 liver 
10 36.45 3.3 3.3 3.3 liver 
11 53.55 2.2 2.2 2.2 liver 
12 46.82 2.5 2.5 2.5 liver 
13 15.02 8 8 8 muscle 
14 15.78 9.5 9.5 9.5 muscle 
15 13.50 8.8 8.8 8.8 muscle 
16 12.99 7.6 7.6 7.6 muscle 
17 15.78 8.9 8.9 8.9 muscle 
18 13.50 9.2 9.2 9.2 muscle 
19 12.45 9.6 9.6 9.6 muscle 
20 11.00 6.0 6.0 6.0 muscle 
21 9.55 10.5 10.5 10.5 muscle 
22 12.45 10.9 10.9 10.9 muscle 
23 11.00 12.5 12.5 12.5 muscle 
24 9.55 9.6 9.6 9.6 muscle 
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Figure 17. SDS-PAGE using 10 µg of liver protein.  
Proteins were extracted from liver tissue using a commercial (C) or an in-house 
(I) lysis buffer and homogenized with the Polytron (A) or the TissueLyser (B). 
Lane 1, Protein ladder, Lanes 2-7 protein lysates. 
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Figure 18. SDS-PAGE using 10 µg of muscle protein.  
Proteins were extracted from muscle tissue using a commercial (C) or an in-house (I) 
lysis buffer and homogenized with the Polytron (A) or the TissueLyser (B). Lane 1, 
Protein ladder, Lanes 2-7 protein lysates. 
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Figure 19. SDS-PAGE using 60 µg of liver protein.  
Proteins were extracted from liver tissue using a commercial (C) or an in-house (I) lysis 
buffer and homogenized with the Polytron (A) or the Tissue Lyser (B). Lane 1, Protein 
ladder, Lanes 2-7 protein lysates. 
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Figure 20. SDS-PAGE using 60 µg of muscle protein.  
Proteins were extracted from muscle tissue using a commercial (C) or an in-house (I) 
lysis buffer and homogenized with the Polytron (A) or the Tissue Lyser (B). Lane 1, 
Protein ladder, Lanes 2-7 protein lysates. 
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3.1.1.4 Selection of protein extraction conditions 
We decided to use the commercial lysis buffer and homogenization with the TissueLyser 
for the extraction of proteins from liver and muscle tissues of experimental samples. This 
extraction method yielded the highest amounts of proteins in the liver and demonstrated 
more high and low molecular weight proteins in muscle compared the other methods 
used.  
 
3.2 Western blot analysis 
Western blot analysis was performed to determine if C. maculata affects AMPK 
activation, as demonstrated for other phytochemicals with anti-obesity effects (Kim et al., 
2008; Niu et al., 2012; Steinberg and Kemp, 2009). Proteins from lean and obese Wistar 
rats that were fed a cafeteria diet (CD) for three months, with or without C. maculata 
treatment, were analyzed. 
 
3.2.1 Protein extraction  
Proteins from the liver and muscle tissue of the experimental samples were extracted 
using the optimized procedures (section 3.1). The total yield of proteins extracted from 
100 mg of liver and muscle tissue of lean and obese CD-fed untreated and C. maculata 
treated rats is indicated in Table 7 and Figure 21.    
 
Cyclopia maculata treatment had no effect on hepatic protein content of lean and obese 
rats (Table 7, Figure 21).  Interestingly protein content was 2.4-fold higher (p<0.001) in 
obese rats compared to lean rats (untreated 26.0 ± 2.2 vs. 11.5 ± 0.6; treated 27.9 ± 2.3 vs. 
11.0 ± 0.8). 
 
Cyclopia maculata treatment similarly had no effect on muscle protein content of lean and 
obese rats (Table 7, Figure 21). Furthermore, although protein yield was increased in 
obese compared to lean rats (untreated 29.4 ± 2.3 vs. 26.8 ± 2.5; treated 30.3 ± 3.6 vs. 
25.7 ± 3.7), the difference was not significant. 
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Table 7. Protein yield of liver and muscle tissue. 
 
 
 
 
 
Protein Yield (mg) 
Non-obese Obese 
CD  
(n=10) 
CD + C. maculata 
(n=10) 
CD  
(n=10) 
CD + C. maculata 
(n=10) 
Liver 11.5 ± 0.6*** 11.0 ± 0.8
†††
 26.0 ± 2.2*** 27.9 ± 2.3
†††
 
Muscle 26.8 ± 2.5 25.7 ± 3.7 29.4 ± 2.3 30.3 ± 3.6 
Protein yield was obtained by multiplying the concentration by the total volume obtained. 
Results are expressed as the average ± standard error of mean. 
***
†††
p<0.001. Lean vs. obese 
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Figure 21. Graphical representation of the protein yield of liver and muscle tissue.  
Proteins were extracted from liver (A) and muscle (B) tissue of lean and obese Wistar rats 
fed a cafeteria diet without (control) or with C. maculata extract (C. maculata), the 
concentrations determined and yield calculated by multiplying the concentration obtained 
by the final volume. Results are expressed as the mean ± standard error of mean (n=10). 
***p < 0.0001. 
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3.2.2 The effect of C. maculata treatment on AMPK expression 
To investigate the effect of C. maculata on AMPK expression, proteins extracted from 
lean and obese Wistar rats were separated by 10% SDS PAGE, transferred to PVDF and 
probed with total AMPK and phosphorylated AMPK (an indication of AMPK activation) 
antibodies.  
 
3.2.2.1 The effect of C. maculata on the expression of total AMPK 
Although a slight increase was observed, C. maculata treatment had no significant effect 
on the expression of total AMPK in the liver of lean (115.4 ± 9.0 vs. 112.8 ± 7.2) and 
obese (126.1 ± 6.6 vs.154.8 ± 13.7) rats (Table 9, Figure 22). The expression of total 
AMPK was increased in liver of control obese rats compared to control lean rats (154.8 ± 
13.7 vs. 112.8 ± 7.2; 1.4-fold, p<0.05).  
 
In muscle, C. maculata treatment decreased AMPK expression in lean rats (606.5 ± 49.4 
vs. 1451.4 ± 335.5; 2.3-fold, p<0.05) (Table 10, Figure 22). Treatment increased 
expression although not significant in obese rats (421.3 ± 54.5 vs. 377.2 ± 66.9). In 
contrast to the liver, the expression of total AMPK was decreased in control obese rats 
compared to control lean rats (377.2 ± 66.9 vs. 1451.4 ± 335.5; 3.8-fold, p<0.0001) 
(Table 10, Figure 22). 
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Figure 22. Total AMPK expression.  
Densitometry blot images of total AMPK expression in liver (A) and muscle (B) tissue of lean and 
obese; control and C. maculata treated rats. Expression was normalized to β-actin or β-tubulin. 
Graphical representation of densitometry results for liver (C) and muscle (D) is expressed as the mean ± 
standard error of mean (n=8). *p < 0.05, *** p < 0.0001.  
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3.2.2.2 The effect of C. maculata on the expression of phosphorylated AMPK 
AMPK activation is signified by its phosphorylation at threonine 172 in the activation 
loop of the α subunit catalytic domain by one or more upstream kinases (Hawley et al., 
2003). Previous studies have demonstrated that plant extracts and phytochemicals may 
mediate their anti-obesity effects via AMPK activation (increase in phosphorylation) 
(Kim et al., 2008; Niu et al., 2012). 
  
Cyclopia maculata treatment did not affect phosphorylated AMPK (pAMPK) expression 
in the liver of lean (120.0 ± 6.2 vs. 113.2 ± 5.6) and obese (117.0 ± 3.7 vs. 121.2 ± 5.8) 
rats (Table 9, Figure 23).  
 
In muscle, C. maculata treatment induced a similar pattern of expression as observed for 
total AMPK; decreased expression of pAMPK was observed in lean rats after treatment 
(46.1 ± 7.9 vs. 246.2 ± 51.8; 5.3 fold, p<0.0001). Treatment did not effect pAMPK 
expression in obese rats (48.0 ± 8.3 vs. 44.5 ± 5.9). Phosphorylated AMPK expression 
was decreased in obese rats compared to lean rats, regardless of treatment (untreated 44.5 
± 5.9 vs. 246 ± 51.8; treated 48.0 ± 8.2 vs. 46.2 ± 7.9) the difference was significant in 
untreated rats only (46.2 ± 7.9 vs. 246 ± 51.8; 3.1 fold, p<0.0001) (Table 10, Figure 23).  
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Figure 23. Phosphorylated AMPK expression.  
Densitometry blot images of phosphorylated AMPK expression in liver (A) and muscle (B) tissue of lean and 
obese; control and C. maculata treated rats. Expression was normalized to β-actin or β-tubulin. Graphical 
representation of densitometry results for liver (C) and muscle (D) is expressed as the mean ± standard error 
of mean (n=8). ***p < 0.0001.  
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3.2.2.3 Phosphorylated AMPK as a ratio of total AMPK (Activated AMPK) 
Activated AMPK expression was determined by dividing the relative phosphorylated 
AMPK expression by the relative total AMPK expression. Cyclopia maculata treatment 
increased AMPK activation in lean (107.6 ± 7.9 vs. 102.4 ± 6.7) and obese (94.2 ± 4.7 vs. 
82 ± 7.2) rats, although the differences was not significant (Table 8, Figure 24). The 
activation of AMPK was found to be lower in the liver  of untreated obese rats compared 
to untreated lean rats (82 ± 7.2 vs. 102.4 ± 6.7; 1.3-fold), but it was not significant (Table 
8, Figure 24).  
 
In muscle, Cyclopia maculata treatment decreased AMPK activation in both lean (8.3 ± 
2.0 vs. 19.0 ± 3.8; 2.3-fold, p<0.05) and obese (11.7 ± 2.1 vs. 15.0 ± 3.9) rats, although 
the decrease observed in obese rats was not significant (Table 8, Figure 24). Similar to the 
results observed in the liver, AMPK activation was decreased in control (15.0 ± 3.9 vs. 
19.0 ± 3.8; 1.3-fold) and C. maculata treated (11.7 ± 2.1 vs. 8.3 ± 2.0) obese rats 
compared to lean rats, although not significant (Table 8, Figure 24).  
 
 
  
Table 8. Activated AMPK expression in liver and muscle of lean and obese rats. 
 
 
 
 
 
AMPK activation 
Lean Obese 
CD  
(n=8) 
CD + C. maculata 
(n=8) 
CD  
(n=8) 
CD + C. maculata 
(n=8) 
Liver 102.4 ± 6.7 107.6 ± 7.9 82 ± 7.2 94.2 ± 4.7 
Muscle 19.0 ± 3.8* 8.3 ± 2.0* 15.0 ± 3.9 11.7 ± 2.1 
AMPK activation was determined by dividing the relative expression of phosphorylated 
AMPK by the total AMPK expression. Results are expressed as the mean ± standard error 
of mean. 
*p < 0.05. 
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Figure 24. Activated AMPK.  
AMPK activity in liver (A) and muscle (B) tissue was determined by dividing the 
expression of phosphorylated AMPK (pAMPK) by the expression of total AMPK 
(tAMPK). Results are expressed as the mean ± standard error of mean (n=8). * p< 0.05. 
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3.2.3 The effect of C. maculata treatment on PPARα expression  
Peroxisomal proliferator activated receptor α (PPARα) is a downstream protein target of 
AMPK activation that is involved in the metabolic regulation of fatty acids by increasing 
fatty acid uptake and β-oxidation (Yoon, 2009 and Lee et al., 2006). PPARα is 
predominantly expressed in tissues with high rates of mitochondrial and peroxisomal fatty 
acid metabolism including the liver, heart, skeletal muscle and kidneys (Yoon, 2009). To 
investigate the effect of C. maculata on lipolysis and β-oxidation, the expression of 
PPARα was determined in liver and muscle of lean and obese control and treated rats.  
 
Cyclopia maculata treatment decreased PPARα expression in lean rats (331.6 ± 55.3 vs. 
444.0 ± 38) although the difference was not significant. In obese rats, treatment decreased 
PPARα expression (738.2 ± 75.3 vs. 1387.4 ± 334.1; 2.7-fold) although not significantly. 
The expression of PPARα expression was 2.7-fold higher in untreated obese rats 
compared to untreated lean rats (1387.4 ± 334.1 vs. 444.0 ± 38; p<0.001). Similarly 
PPARα expression was higher in C. maculata treated obese compared to C. maculata 
treated lean rats (738.2 ± 75.3 vs. 331.6 ± 55.3) although not significant (Table 9, Figure 
25).  
 
The expression of PPARα in muscle was too low for Western blot analysis and 
quantification.  
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Figure 25. PPARα expression.  
Densitometry blot images of PPARα expression in liver (A) and muscle (B) tissue of lean and 
obese; control and C. maculata treated rats. Expression was normalized to β-actin or β-tubulin. 
Graphical representation of densitometry results for liver (C) and muscle (D) is expressed as the 
mean ± standard error of mean (n=8). **p < 0.001. 
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3.2.4 The effect of C. maculata treatment on UCP2 expression  
To investigate the effect of C. maculata on the β-oxidation of free fatty acids, the 
expression of uncoupling protein 2 (UCP2) was measure in the liver and muscle of lean 
and obese rats. UCP2 uncouples ATP and heat production from the metabolism of free 
fatty acids (Yonezawa et al., 2009; Schrauwen and Hesselink, 2002).  
 
Cyclopia maculata treatment increased UCP2 expression in the liver of lean (1605 ± 
379.4 vs. 1541.1 ± 287.2) and obese (4952.4 ± 1473 vs. 4604.1 ± 1057) rats, although not 
significant (Table 9, Figure 26). UCP2 expression was 2.9-fold higher, although not 
significant in the liver of control obese rats compared to control lean rats (4604.1 ± 1057 
vs. 1541.1 ± 287.2 1) (Table 9, Figure 26).  
 
In muscle, C. maculata treatment decreased UCP2 expression in lean rats (337.6 ± 31.6 
vs. 937.7 ± 86.6; 2.8-fold, p<0.0001) (Table 10, Figure 26). Similarly treatment decreased 
UCP2 expression in obese rats, although it was not significant (372.7 ± 53.1 vs. 500.3 ± 
66.1). Contrary to the liver, UCP2 expression was 1.4-fold higher in control lean rats 
compared to control obese rats (937.7 ± 86.6 vs. 500.3 ± 66.1; p<0.0001) (Table 10, 
Figure 26). 
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Figure 26. UCP2 expression.  
Densitometry blot images of total AMPK expression in liver (A) and muscle (B) tissue of 
lean and obese; control and C. maculata treated rats. Expression was normalized to β-actin 
or β-tubulin. Graphical representation of densitometry results for liver (C) and muscle (D) 
is expressed as the mean ± standard error of mean (n=8). ***p < 0.0001.  
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     Table 9. Summary of Western blot results for liver tissue. 
Protein of 
interest 
†Expression 
Lean rats Obese rats 
Cafeteria diet 
(n=8) 
Cafeteria diet +  
C. maculata  
(n=8) 
Cafeteria diet (n=8) Cafeteria diet + 
C. maculata 
(n=8) 
tAMPK 112.8 ± 7.2* 115.4 ± 9.0 154.8 ± 13.7* 126.1 ± 6.7 
pAMPK 113.2 ± 5.6 120.0 ± 6.2 121.2 ± 5.8 117.0 ± 3.7 
PPAR-α 444.0 ± 38.0*** 331.6 ± 55.3 1387.4 ± 334.1*** 738.2 ± 75.36 
UCP-2 1541.1 ± 287.2 1605 ± 379.4 4604.1 ± 1057 4952.4 ± 1473 
PPAR-γ ND ND ND ND 
ACC ND ND ND ND 
†Expression was calculated by normalizing to β actin or β-tubulin  
Results are expressed as the mean ± standard error of mean 
ND indicates that the Western blot failed to identify the protein of interest 
* p < 0.05, *** p < 0.0001. 
 
Table 10. Summary of Western blot results for muscle tissue. 
Protein of 
interest 
†Expression 
Lean rats Obese rats 
Cafeteria diet (n=8) Cafeteria diet +  
C. maculata  
(n=8) 
Cafeteria diet (n=8) Cafeteria diet + 
C. maculata (n=8) 
tAMPK 1451.4 ± 335.5*††† 606.5 ± 49.4* 377.2 ± 66.9††† 421.3 ± 54.5 
pAMPK 246.2 ± 51.8***††† 46.2 ± 7.9*** 44.5 ± 5.9††† 48.0 ± 8.3 
UCP-2 937.7 ± 86.6***††† 337.6 ± 31.6*** 500.3 ± 66.1***††† 372.7 ± 53.1 
PPAR-α ND ND ND ND 
PPAR-γ ND ND ND ND 
ACC ND ND ND ND 
†Expression was calculated by normalizing to β-tubulin  
Results are expressed as the mean ± standard error of mean 
ND indicates that the Western blot failed to identify the protein of interest. 
*p < 0.05, ***
†††
p < 0.0001. 
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3.2.5 Other proteins investigated  
Investigation of the effect of Cyclopia maculata treatment on Peroxisome proliferator 
activated receptor gamma (PPAR) and acetyl CoA carboxylase (ACC) was unsuccessful. 
PPAR is the rate limiting transcriptional regulator involved in adipocyte differentiation 
and growth (Wu et al., 2010). Regulation of PPAR activity by pharmaceutical and 
phytochemical treatments decreases adipogenesis, triglyceride accumulation and body 
weight gain (Hwang et al., 2007). Western blot analysis of PPAR for liver and muscle 
tissue resulted nonspecific background binding with no quantifiable distinctive protein 
bands (Table 9 and 10).  
 
ACC is the rate limiting enzyme for the conversion of acetyl CoA to malonyl-CoA, either 
for fatty acid synthesis or inhibition of β-oxidation by the blocking of carnitine palmitate 
tranferase 1 (CPT1) (Coleman et al., 2002). Inhibition of ACC through its direct 
phosphorylation by AMPK reduces fatty acid synthesis and promotes the β-oxidation of 
long fatty acids and decrease body weight gain (Do et al., 2012). Western blot analysis of 
ACC for liver and muscle tissue was unsuccessful due to nonspecific background binding 
with no quantifiable distinct protein bands (Table 9 and 10). 
 
3.3 Phosphorylated AMPK ELISA  
An ELISA was used to confirm our Western blot results for phosphorylated (activated) 
AMPK. The ELISA measures the expression of AMPK phosphorylated at threonine 172 
and results are given relative to total AMPK. The ELISA therefore does not indicate 
absolute values of total and phosphorylated AMPK, but rather the ratio of pAMPK to 
tAMPK. 
 
ELISA confirmed Western blot results where a slight increase in the activation of AMPK 
was observed in the liver of lean (23.7 ± 7.0 vs. 22.1 ± 6.4) and obese rats (21.1 ± 6.6 vs. 
19.9 ± 4.3) after C. maculata treatment, although not significant (Table 11, Figure 27).   
 
 
 
 
 
86 
 
Due to financial constraints, only the muscle tissue of lean rats was investigated by 
ELISA. In contrast to Western blot analysis where C. maculata treatment decreased 
AMPK activation in lean rats (although not statistically significant), ELISA showed no 
effect (2.0 ± 1.1 vs. 1.7 ± 1.5) (Table 11, Figure 27).  
 
Table 11. ELISA results  
 
 Lean rats Obese rats 
CD (n=10) CD + C. maculata (n=10) CD (n=10) CD + C. maculata (n=10) 
Liver 22.1 ± 6.4 23.7 ± 7.0 19.9 ± 4.3 21.1 ± 6.6 
Muscle 1.7 ± 1.5 2.0 ± 1.1 ND ND 
The AMPKα [pT172] kit from Invitrogen is a solid phase sandwich enzyme linked 
immunosorbent Assay (ELISA). A monoclonal antibody specific to AMPKα is coated on 
a microtiter strip which binds to AMPKα protein in tissue lysates, trapping it to the 
microtiter strip. The addition of an antibody directed at AMPKα phosphorylated at 
Thr172 binds to the immobilized AMPKα protein if phosphorylated 
‡
Results are expressed as the average ± standard error of mean 
ND, not determined.  
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Figure 27. Phosphorylated AMPK [pT172] ELISA results. 
(A) Phosphorylated AMPK expression in liver (A) and muscle (B) of lean and obese 
Wistar rats. Results are expressed as the average ± standard error of mean. 
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3.4 Histological analysis of retroperitoneal fat of Wistar rats 
Haematoxylin and Eosin (H&E) staining of the retroperitoneal fat (RF) pads was 
performed to determine the effect of C. maculata treatment on fat accumulation and 
adipocyte morphology. Retroperitoneal fat is an important visceral fat depot store and is 
sensitive to the storage and release of fatty acids, thereby influencing their morphology 
and cell number (Bjørndal et al., 2011). Lipid metabolic regulatory effects of C. maculata 
could possibly be observed in the morphology and number of adipocytes in this active 
visceral fat depot.  
 
Cyclopia maculata treatment did not affect adipocyte size in lean (106397 ± 1993 vs. 
106779 ± 3758) and obese (102834 ± 1838 vs. 107612 ± 1393) rats (Table 12, Figure 28). 
 Adipocyte size was increased in obese compared to lean rats, but was not significant 
(Table 12, Figure 28).  
 
Cyclopia maculata treatment did not affect the number of adipocyte in lean (8.2 ± 0.9 vs. 
8.2 ± 1.2) rats; a slight increase in obese (8.0 ± 0.7 vs. 7.6 ± 0.4) rats, but it was not 
significant. The number of adipocyte observed in the retroperitoneal fat of obese was 
lower than that in lean rats, although not significant (Table 12, Figure 28).  
 
Table 12. Histological results of retroperitoneal fat. 
 
 Lean rats Obese rats 
CD (n=10) CD + C. maculata 
(n=10) 
CD (n=10) CD + C. maculata 
(n=10) 
Adipocyte 
size  
106779 ± 
3758 
106397 ± 1993 
 
107612 ± 
1393 
102834 ± 1838 
 
Adipocyte 
number 
8.2 ± 1.2 8.2 ± 0.9 7.6 ± 0.4 8.0 ± 0.7 
Results for adipocyte size are expressed as arbitrary units, while the number of adipocytes 
per microscopic field (average of 10 fields) is given. 
Results are expressed as the average ± standard error of mean 
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Figure 28. Histological results of retroperitoneal fat. 
Adipocyte size (A) and number (B) in the retroperitoneal fat pads of lean and 
obese Wistar rats fed the cafeteria with or without the C. maculata extract. Results 
are expressed as the as the average ± standard error of mean. 
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4. Discussion 
Natural plants and their phytochemicals possess a number of health effects including anti-
oxidant, anti-mutagenic, anti-inflammatory and anti-cancer properties, mediated by 
activating the AMPK signaling pathway (Hwang et al., 2009). The increase in AMPK 
expression and phosphorylation by phytochemicals including mangiferin, a constituent of 
C. maculata has been shown to regulate body weight gain by promoting lipid catabolism 
(Niu et al., 2012). Recent investigations in our laboratory have shown that a hot water 
extract of fermented C. maculata regulates lipid metabolism in vitro (Dhudia et al., 2013). 
Patel investigated the effect of C. maculata on diet-induced obesity in Wistar rats (Patel, 
2012). The aim of this study was to investigate whether C. maculata treatment in Wistar 
rats activates the AMPK signaling pathway. 
 
4.1 Protein optimization 
Protein lysate purity is important during Western blot analysis. Salts, debris and other 
impurities may impede the migration of proteins during SDS-PAGE (Westermeier, 2000). 
Furthermore, impurities may contain enzymes and compounds which degrade proteins. 
Impurities may also result in smearing of gels, hindering protein band visibility and 
density, thus causing bands to be indistinguishable, resulting in non-specific binding of 
antibodies to proteins of interest during western blot analysis 
 
Protein extraction was optimized by comparing two different lysis buffers and two 
different homogenization methods, and using two different tissues, liver and muscle. The 
protein yield of liver was significantly higher when the commercial lysis buffer was used 
compared to the in-house lysis buffer, with both methods of homogenization. The 
TissueLyser homogenization method was superior to the Polytron, in terms of protein 
yield. The different optimization methods yielded no significant differences in muscle 
tissue, thus the commercial lysis buffer and the TissueLyser was selected for protein 
extraction from liver and muscle tissue samples. Protein yield for the liver was also 
significantly higher compared to muscle protein yield, irrespective of lysis buffer and 
homogenization method used. Protein content differences between the liver and muscle 
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may be due to the different structure and function of these tissues. The liver is a soft tissue 
consisting of simple hepatocytes whereas muscle is composed of striated rigid fibers that 
do not lyse easily. 
 
The commercial lysis buffer contains a proprietary detergent and was supplemented with 
protease and phosphatase inhibitor tablets according to the manufacturer’s instructions, 
whereas the in-house lysis buffer was prepared according to our standard operation 
procedure for protein extraction and was supplemented with less protease and 
phosphatase inhibitor tablets. The difference in protein yield obtained between the two 
extraction buffers may be due to the greater ability of the commercial lysis buffer to 
protect against enzymatic degradation by phosphatase and protease enzymes in the 
lysates, as well as the proprietary detergent removing excess salts and debris thereby 
increasing lysate purity and quality.  
 
For liver samples, the TissueLyser was superior to the Polytron. Differences in the protein 
yield between the TissueLyser and the Polytron may be due to their different 
homogenization procedures. The TissueLyser works by high speed crushing of the tissue 
with steel beads and the Polytron homogenizes tissue with a serrated blade. Furthermore, 
during homogenization with the Polytron the lysate is transferred to multiple tubes which 
may lead to a loss in volume. The TissueLyser homogenization is a single step process in 
which homogenization occurs in a 2 ml tube without volume loss. The Polytron yielded 
residual debris after homogenization which may also account for its reduced protein yield 
compared to the TissueLyser. 
 
4.2 Lean and obese rats 
A lean and an obese group (Patel, 2012) were used for this study. The lean rats were 21 
day old weanlings who were fed the cafeteria diet over the experimental period of 12 
weeks. The obese rats were 21 day old weanlings who were fed a cafeteria diet for 16 
weeks ad libitum to induce nutritional obesity prior to the experimental period (3 months). 
Both groups of rats were treated with the hot water extract of fermented C. maculata at a 
dose of 300 mg/kg throughout the 3 month experimental period. The lean rats that were 
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treated with the C. maculata extract had a 2.4% reduction in body weight gain at the end 
of the study, whereas the obese rats showed a 2.4% increase in body weight gain over the 
experimental period. These two groups were investigated to determine how C. maculata 
treatment affected AMPK activity in lean and obese individuals.  
 
4.3 Western blot analysis  
4.3.1 Protein yield results 
Proteins were extracted with an optimized method using the commercial lysis buffer and 
the TissueLyser as described previously. Cyclopia maculata treatment did not affect the 
protein yield of liver and muscle tissue of lean and obese rats. Interestingly, 100 mg of 
liver tissue from obese rats yielded significantly more proteins than 100 mg of liver tissue 
from lean rats. The increased protein yield observed in the livers of obese rats compared 
to lean rats, is possibly part of an adaptive response to the increased lipid overload from 
the cafeteria diet (Estornell et al., 1995; Fillios and Saito, 1965). Increased hepatic protein 
turnover in obese fa/fa Zucker rats and in obese woman has been linked to increased 
microsomal and peroxisomal protein turnover in response to lipid over feeding (Estornell 
et al., 1995; Fillios and Saito, 1965). The increased protein turnover is thought to 
facilitate the synthesis of enzymes to regulate the increased lipid accumulation within 
cells (Waterlow et al., 1995; Fillios and Saito, 1965).  
 
Similar to the liver, the protein yield in muscle tissue of obese rats was higher to the 
protein yield obtained in lean rats, although the difference was not statistically significant. 
Difference in protein yield between tissues is suggested to be dependent on tissue 
structure and functional activity (Anderson et al., 2008; Hwang et al., 2010). Our results 
suggest that the liver, and to a lesser extent the muscle, is an important site for protein 
synthesis in the obese state. Contrary to the optimization experiment, no difference in 
protein yield was observed between liver and muscle of lean and obese rat. Difference in 
protein yield between experiments could be due to differences in the tissue samples for 
the optimization experiments.  
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4.3.2 Cyclopia maculata and AMPK activity (pAMPK/tAMPK) 
Recent investigations have shown that many plants mediate their biological actions by 
inducing the AMPK pathway (Kim et al., 2008; Do et al., 2012; Kang et al., 2012).  The 
effect of C. maculata treatment on AMPK activity was determined as the ratio of 
pAMPK/tAMPK.  
 
Although total AMPK was significantly higher in the liver of obese rats, activated AMPK 
(pAMPK/tAMPK) was lower in these rats. Total AMPK and activated AMPK were lower 
in the muscle of obese rats. Other studies have reported that AMPK activity is 
dysregulated in the liver and muscle during lipid overload, obesity and raised blood 
glucose levels (Martin et al., 2006; Kraegen et al., 2006). The obese rats used in this study 
were fed a cafeteria diet to induce obesity and insulin resistance (Patel, 2012), possibly 
explaining the decreased AMPK activity in these rats. Furthermore, the blood glucose 
concentrations of these rats were raised, and they were 4 months older than lean rats 
(Patel, 2012), further contributing to the decreased AMPK activity observed.   
 
Although a slight increase in AMPK activity was observed after C. maculata treatment in 
the liver of lean and obese rats, the difference was not statistically significant. In muscle, 
C. maculata treatment decreased AMPK activity in lean and obese rats. Glycogen 
accumulation is known to inhibit AMPK activity (Viollet et al., 2003; Mcbride et al., 
2009). Chellan et al. (2012) showed than another South African plant Athrixia 
phylicoides, stimulates glycogen accumulation, thus making it tempting to speculate that 
C. maculata also stimulates glycogen accumulation and that the decreased AMPK activity 
observed after C. maculata treatment is due to increased glycogen accumulation in the 
muscle of these animals. In support of this idea, other Cyclopia species have been shown 
to stimulate glucose uptake and utilization (Muller et al. 2012).  
 
AMPK activity is tissue specific and differences in AMPK activity in the muscle and the 
liver have been reported (Viollet et al., 2010). AMPK may be expressed as 12 different 
isoforms, conferring different properties depending on their subcellular location (Amodeo 
et al., 2007). AMPK activity in the liver results in the overall inhibition of energy 
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consuming pathways, whereas AMPK activation in skeletal muscle results in the 
activation of ATP producing catabolic pathways, depending on their isoform combination 
and stimulus (Suzuki et al., 2007). 
 
Although the beneficial effects of AMPK activation have been well reported (Kang et al., 
2012), some evidence for the beneficial effects of AMPK inhibition during stroke and 
cancer has been reported (Li et al., 2007). The over activation of AMPK in response to 
ischemic injury is detrimental during ischemic reperfusion which my lead to further 
energy failure and cell death (McCullough et al., 2005; Viollet et al., 2010). AMPK 
inhibition by compound C was shown to provide sustained neuroprotection after stroke, 
benefiting cell survival (Li et al., 2007).  
 
4.3.3 Cyclopia maculata and PPARα expression 
The peroxisomal proliferator activated receptor α (PPARα) is a ligand activated 
transcription factor that belongs to the steroid hormone PPAR superfamily. Other 
members include PPARγ and PPARδ, each with their own ligand and tissue specific 
functions (Evans et al., 2004; Yoon et al., 2009). PPARα is predominantly expressed in 
tissues with high rates of mitochondrial and peroxisomal fatty acid metabolism such as 
the liver, heart, brown adipose tissue, skeletal muscle and kidneys (Yoon et al., 2009). 
PPARα functions by regulating the gene expression of key enzymes involved in the 
transport, uptake and oxidation of lipids such as fatty acid transport protein, carnitine 
palmityol transferase-1 (CPT1) and the uncoupling proteins (UCP1, UCP2 and UCP3) 
(Evans et al., 2004; Yoon et al., 2009). PPARα is activated by high circulating free fatty 
acids, fibrates, ligand steroids and various hormones including leptin and adiponectin 
(Kersten et al., 1999; Armstrong and Towle, 2001). PPARα has been shown to be a 
downstream protein target of the AMPK pathway, activated under conditions of energy 
deprivation and lipid overload (Armstrong and Towle 2001).  
 
PPARα expression was significantly higher in the liver of obese rats compared to their 
lean counterparts. PPARα gene expression is associated with Fatty acid synthase (FAS) 
expression and is regulated by lipid content (Chakravarthy et al., 2009). Increased PPARα 
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expression is associated with increased circulating free fatty acids and their derivatives 
during a high fat diet (Armstrong and Towle, 2001), thus possibly explaining the 
increased PPARα expression in obese rats. 
 
Cyclopia maculata treatment decreased PPARα expression in the liver of both lean and 
obese rats. Dudhia (2012) also demonstrated decreased PPARα protein expression in 3T3-
L1 adipocytes after C. maculata treatment. In this study, decreased PPARα protein 
expression correlated with decreased expression of PPAR and adipogenesis.  
 
Cyclopia maculata was shown to possess phytoestrogen activity (Verhoog, 2006). 
Phytoestrogens are plant polyphenols with estrogen activity (Cederroth et al., 2008). 
Estrogens have been shown to reduce PPARα activity (Jeong et al., 2004; Yoon et al., 
2009), thus possibly explaining the decreased PPARα expression in the rats after C. 
maculata treatment 
 
4.3.4 The effect of C. maculata on uncoupling protein 2 expression 
Uncoupling proteins (UCPs) are mitochondrial transporters present in the inner 
mitochondrial membrane (Villarroya et al., 2007). UCP1 was the first one to be identified 
and plays an important role in the adaptive thermogenesis of brown adipose tissue (Del et 
al., 2000). The UCP1 protein was found to enhance the uncoupling of protons down the 
respiratory chain in the mitochondria for the production of heat in response to cold 
temperatures or high circulating fatty acids (Nicholls and Locke, 1985). UCP2 and UCP3 
were recently identified sharing 72% and 57% amino acid homology to UCP1 (Fleury et 
al., 1997; Gimeno et al., 1997). UCP2 is ubiquitously expressed in a variety of tissues in 
the body, including the skeletal muscle, white adipose tissue, liver, spleen, lungs and 
macrophages (Armstrong and Towle, 2001). UCP3 is predominantly expressed in skeletal 
muscle (Weigle et al., 1998). Unlike UCP1 which is solely involved in the adaptive 
thermogenesis to cold temperatures, UCP2 and UCP3 have been shown to respond to high 
circulating FFAs and reactive oxygen species (ROS), conferring to them lipid metabolic 
regulatory functions (Samec et al., 1998).  UCPs are activated by unsaturated fatty acids 
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and are under the transcriptional control of PPARα and PGC1 which are downstream 
components of the AMPK pathway (Jager et al., 2007).  
 
Cyclopia maculata treatment did not effect UCP2 expression in the liver of lean and 
obese rats. However, UCP2 expression in the liver of obese rats was 2.9-fold higher 
compared to lean rats.  Over feeding and a diet high in unsaturated fats has been 
associated with increased expression of UCP1, a homologue of UCP2, in brown adipose 
tissue and skeletal muscle of rodents decreasing the metabolic efficiency and preventing 
the development of obesity (Himms-Hagen, 1984). Fasting has been associated with an 
increase in metabolic efficiency and a decrease in UCP1 expression and activity 
(Rothwell et al., 1984). Thus the increased UCP2 expression in the liver of obese rats may 
be due to increased adiposity and circulating free fatty acids caused by the cafeteria diet. 
UCP2 has been shown to regulate free radical production from fatty acid oxidation, by 
reducing the proton gradient across the mitochondrial membrane preventing damage to 
lipids, proteins and DNA by ROS (Schrauwen and Hesselink, 2002). Increased UCP2 
expression in obese rats may be due to the fact that these rats were older and have 
increased ROS production (Samec et al., 1998; Katsanos et al., 2009).  
 
In muscle, UCP2 protein was decreased in obese rats and after C. maculata treatment of 
lean rats. These results differ to those observed in the liver and is possibly is due to tissue 
specificity of UCP2. UCP3 is the predominant UCP in muscle (Rousset et al., 2004). The 
decreased UCP2 expression after C. maculata treatment in lean rats could be due to an 
adaptive response, where C. maculata decreases ROS due to its anti-oxidant properties 
(Marnewick et al., 2000; Joubert et al., 2008) and thus leads to less UCP2 expression. 
However, this is a speculation and requires further investigation.  
 
4. 4 Phosphorylated AMPK [pT172] ELISA  
ELISA results, similar to Western blot results, showed that C. maculata treatment 
increased AMPK activation, although not significantly.  
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ELISA is a quantitative assay that investigates intact native proteins whereas Western blot 
is a semi quantitative assay that investigates denatured proteins (Yang and Ma, 2009). 
ELISAs are easier to perform and are less time-consuming than Western blots. However, 
Western blots may give information about protein purity and size, whereas ELISAs do 
not.  
 
4.5 Adipocyte size and number 
Obesity is known to be due to the enlargement of adipose tissue to store excess energy 
intake (Jo et al., 2009). Adipose tissue grows by two mechanisms: hyperplasia, which is 
the increase in cell number and hypertrophy, which is the increase in adipocyte size (Jo et 
al., 2009).  Adiposity is influenced by diet and genetic susceptibility of a person to its 
environment and their interaction (Marti et al., 2009; Prentice, 2006). Adipose tissue itself 
is stored in special depots such as the visceral and subcutaneous fat depots, whose rates of 
adiposity are determinants of weight gain and obesity (Matsuzawa et al., 1995; Huang et 
al., 2001). The investigation of these depots by visual staining techniques such 
Haematoxylin and Eosin staining has provided crucial phenotypical evidence of adipocyte 
size and number, influenced by nutritional intake and genetic susceptibility (Pang et al., 
2008; Azin et al., 2000). 
 
Cyclopia maculata treatment did not significantly affect adipocyte number and size in the 
retroperitoneal fat of lean ad obese Wistar rats. The retroperitoneal fat is a depot of 
visceral fat accumulation which is detrimental in the development of obesity and 
metabolic syndrome (Huang et al., 2001). Anti-obesity treatments have been shown to 
decrease adipocyte hyperplasia and hypertrophy in visceral fat depots such as 
retroperitoneal fat (Pang et al., 2008).  
 
The failure to observe significant differences in adipocyte size and number between lean 
and obese rats is unexpected and could be due to technical difficulties with the 
quantification method used. Due to time constraints, it was not possible to repeat the 
analysis.  
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4.6 Limitations of study and future work 
The main limitation of the study is the small weight reduction observed in these rats after 
C. maculata treatment. This could possibly explain our failure to observe AMPK 
activation. Furthermore, it has been suggested that AMPK activation plays a more 
prominent role in genetic models of obesity compared to diet-induced models of obesity. 
Testing of different doses of C. maculata could improve bioactivity (weight reduction) 
and AMPK activation.  
 
C. maculata decreased UCP2 expression in the muscle of lean rats, but not in obese rats. 
However, no difference in UCP2 expression in the liver was observed after treatment. 
Future studies should focus on investigation of these tissue specific differences as it may 
provide important clues about metabolic regulation in lean and obese individuals.   
 
4.7 Conclusion 
Safe effective treatments to combat weight gain and obesity have become a serious 
concern due to the increased prevalence of obesity and the metabolic syndrome epidemic. 
Phytochemical treatments have been shown to regulate weight gain and reduce the 
detrimental effects of obesity in the development of NCDs, exhibiting their effects 
through the regulation of key metabolic process, such as AMPK signaling. Cyclopia 
maculata is a polyphenolic rich plant with a range of biological activities including anti-
mutagenic, anti-oxidative, anti-cancer and phytoestrogen activity. This study has shown 
that treatment of diet-induced obese Wistar rats with 300 mg/kg of C. maculata does not 
affect the AMPK signaling pathway.  
 
Although treatment did not affect AMPK activation in lean and obese rats, protein content 
in the liver of obese animals was increased compared to their lean counterparts. Similarly, 
an increase in PPARα and UCP2 expression was observed in obese rats compared to lean 
rats and suggests an adaptive response to the increased circulating free fatty acids and an 
increase in β-oxidation in these animals. 
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Appendix A 
 
Materials       Suppliers 
 
Protein extraction 
 
 Glass plate  BioRad, (USA) 
 Scalpel and blades  Sigma-Aldrich (USA) 
 Forceps    
    
 Lasec (RSA) 
 100% ethanol   
     
 B&M Scientific (RSA)  
 Gloves    
     
 Lasec (RSA) 
 Paper towels   
     
 Nampak (RSA) 
 Weighing paper  
     
 Lasec (RSA) 
 Ice    
     
 Ice making machine 
 Liquid nitrogen   
    
 Afrox (RSA) 
 Eppendorf tubes 2 ml, 1.5 ml, 
0.5 ml     
 Sigma-Aldrich (USA) 
 Phosphate buffered saline (PBS)
      
 Roche (Germany) 
 Standard lysis buffer  
     
 According to SOP 
 Tissue extraction reagent lysis 
buffer     
 Invitrogen (USA) 
 Trizma base   
     
 Sigma-Aldrich (USA) 
 Glycine    
    
 Sigma-Aldrich (USA) 
 NaCl    
     
 B & M Sci (RSA) 
 DTT     
     
 Sigma-Aldrich (USA) 
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 NaF    
     
 Sigma-Aldrich (USA) 
 Na3VO4    
     
 Sigma-Aldrich (USA) 
 NP40    
     
 Sigma-Aldrich (USA) 
 Triton X 1140   
     
 Sigma-Aldrich (USA) 
 RNase    
     
 Sigma-Aldrich (USA) 
 1 x Protease inhibitor cocktail 
tablets     
 Roche (Germany) 
 1 x Phosphatase inhibitor  tablets 
     
 Roche (Germany) 
 PMSF    
     
 Thermo Scientific (USA) 
 Stainless steel beads  
     
 Qiagen (Germany) 
 Pipette tips 10 µl, 20 µl, 100 µl, 
200 µl and 1000 µl   
 Sigma-Aldrich (USA) 
 
Protein determination 
 
 BioRad DC assay reagent kit  BioRad, (USA) 
 BSA  BioRad, (USA) 
 96 well microtiter plate  Sigma-Aldrich (USA) 
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SDS-PAGE  
 
 Leammli sample buffer                                    BioRad (USA) 
 β-mercapatoethanol   Sigma-Aldrich (USA) 
 
 TEMED   Sigma-Aldrich (USA) 
 
 40% Acrylamide  BioRad, USA (USA)  
 SDS  Sigma-Aldrich (USA) 
 APS  Sigma-Aldrich (USA) 
 Protein loading tips   Sigma-Aldrich (USA) 
 Precision Plus Dual Color 
Marker 
 Thermo Scientific (USA) 
 Fermentes Pre-stain Protein 
ladder  
 Thermo Scientific (USA) 
 Fermentes Un-stain Protein 
ladder  
 Thermo Scientific (USA) 
 Cruz marker  SantaCruz (USA) 
 Coomassie brilliant blue  BioRad (USA)  
 
Western blot 
 
 Ponceau Stain   
     
 Sigma-Aldrich (USA) 
 Hybond-P (PVDF) membrane 
     
 Millipore (USA) 
 Whatmann paper  
     
 Whatman Ltd (UK) 
 Non-fat milk powder  
     
 Clover (RSA) 
 LumiGlo Chemiluminescent 
Substrate kit    
 KPL (USA) 
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Primary antibodies  
 
Antibody Source Type  Cat number Supplier 
 pAMPK Rabbit mAb #2535 Cell Signalling 
(USA) 
 tAMPK Rabbit pAb #2757 Cell Signalling 
(USA) 
 ACC Rabbit mAb C20G5 Cell Signalling 
(USA) 
 UCP2 Goat mAb AB77363 Abcam (USA) 
 PPAR Rabbit mAb #2430 Cell Signalling 
(USA) 
 PPARα Rabbit pAb AB3484 Abcam (USA) 
 β-tubulin Rabbit pAb #2146 Cell Signalling 
(USA) 
 β-actin Mouse mAb  SC47778 SantaCruz 
(USA) 
 
Secondary antibodies  
 
Antibody Source Cat number Supplier 
 Mouse HRP† IgG Donkey #2535 Cell Signalling 
(USA) 
 Rabbit HRP IgG Donkey #2757 Cell Signalling 
(USA) 
 Goat HRP IgG Donkey C20G5 Cell Signalling 
(USA) 
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ELISA 
AMPKα [pT172] ELISA kit    Invitrogen (USA) 
 
Reagent 96 Test kit 
 AMPKα [pT172] standard  2 vials 
 Standard diluent buffer  1 bottle 
 Antibody coated wells, 12 x 8 
well strips 
 1 plate 
 AMPKα [pT172] Detection 
antibody 
 1 bottle 
 Anti-rabbit IgG HRP (100 X)  1 vial 
 HRP Diluent  1 bottle 
 Wash buffer concentrate (25 X)  1 bottle 
 Stabilized Chromogen, 
Tetramethylbenzidine (TMB) 
 1 bottle 
 Stop solution  1 bottle 
 Plate covers, adhesive strips  3 
 
Histology 
 Glass slides  Lasec (RSA) 
 Haematoxylin  Lasec (RSA) 
 Eosin  Lasec (RSA) 
 100% Ethanol  B&M Scientific (RSA) 
 Xylene  Merck (Germany) 
 Entallen  Merck (Germany) 
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Equipment 
 
 Analytical balance  
     
 Ohaus (UK) 
 TissueLyser   
     
 Qiagen (Germany) 
 Polytron homogenizer 
    
 Brinkmann/Kinematica 
(Switzerland)   
 Centrifuge   
     
 Labnet Inc. (USA) 
 ELISA plate reader  
     
 BioTek (USA) 
 Plate shaker   
     
 IKA® (Germany) 
 BioRad Mini Protean Tetra Cell
     
 BioRad (USA) 
 BioRad, USA power pac HC 
     
 BioRad, (USA) 
 Heating block   
     
 Labnet (USA) 
 BioRad, USA ChemiDocTM 
XRS
+ 
image illuminator 
  
 BioRad (USA) 
 Quantity One software 
     
 BioRad (USA) 
 Ice making machine  
     
 Scotsman (USA) 
 Pasteur pipettes  
     
 Labnet Inc. (USA) 
 Greiner (Germany) 
 Belly dancer/shaker  
     
 StoVoll (USA) 
 Olympus BX50 light 
microscope  
 Olympus (Japan) 
 NIS-Element BR 3.0 software   Nikon instruments Inc,( USA) 
 Leica Qwin pro version 3   Leica Microsystems, Germany 
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Appendix B  
Solutions 
 
Protein extraction  
1 M Tris, pH 7.5 
Stock   Volume   Final Concentration 
Tris, MW=121.1   12 g    1M 
ddH2O     100 ml 
pH to 7.5 with HCl 
Make up to 100 ml with ddH2O 
50 mM Tris, pH 7.5 
Stock   Volume   Final Concentration 
1M Tris, pH 7.5  2.5 ml   50 mM 
ddH2O     to 50 ml 
 
1 mM DTT  
Stock   Volume   Final Concentration 
DTT, MW= 41.9 9  8 mg   50 mM 
Lysis buffer    to 50 ml 
 
100 mM PMSF  
Stock   Volume   Final Concentration 
PMSF, MW=174.194  870 mg  100 mM 
Isopropanol    to 50 ml 
1 ml aliquots were stored at -20˚C 
  
50 mM NaF 
Stock  Volume   Final Concentration 
NaF, MW= 41.9 g/mol  0.104 g   50 mM 
ddH2O  to 50 ml 
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200 mM Na3VO4, pH 10 
Stock Volume   Final Concentration 
Na3VO4, MW=183.91 g/mol   367.82 mg   200 mM 
ddH2O to 100 ml  
 
10 mM Na3VO4   
Stock  Volume   Final Concentration 
200 mM Na3VO4  10 ml   10 mM 
ddH2O  to 200 ml  
1 ml aliquots were stored at -20˚C  
    
70% Ethanol 
Stock  Volume   Final Concentration 
100%  700 ml   70% 
ddH2O  to 1 liter 
 
In-house lysis buffer 
Stock   Volume   Final Concentration 
1M Tris  2.5 ml   50 mM 
100 mM DTT    0.8 mg   1mM 
NaF  104 mg  50 mM 
Na3VO4  500 µl   100 µM 
NP40     500 µl   1%,  
Triton     500 µl   1%  
RNase     12.5 µl   25 µg/ml  
Protease inhibitors   2 tablets  1x 
Phosphatase inhibitors  5 tablets  1x 
ddH2O     to 50 ml 
Make 1 ml aliquots and store at -20°C. 
100 mM PMSF    10 µl   1 mM 
Add PMSF before use. 
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Commercial lysis buffer  
Stock Volume   Final Concentration 
1 M Tris   50 mM 
NaCl   250 mM 
EDTA    5 mM, 
Na3VO4   2 mM  
NaF   1 mM 
Na4P2O7    20 mM,  
NaN3    0.02% 
Proprietary detergent 
Protease inhibitors   10 tablets  1x 
Phosphatase inhibitors  10 tablets  1x 
ddH2O     to 100 ml 
Make 1 ml aliquots and store at -20°C 
100 mM PMSF    10 µl   1 mM 
Add PMSF before use 
 
Protein determination 
Solution A 
Stock Volume   Final Concentration 
BioRad, USA DC Reagent S 20 µl    
BioRad, USA DC Reagent A 1 m 
 
SDS PAGE 
2x Sample buffer 
Stock   Volume   Final Concentration 
β-mercaptoethanol  50 µl  
Leammli sample buffer  950 µl  
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10% SDS 
Stock  Volume   Final Concentration 
SDS  10 g    10% 
ddH2O   to 100 ml 
 
10% APS 
Stock  Volume   Final Concentration 
APS  100 mg  10% 
ddH2O   in 1 ml 
  
10% Resolving gel  
Stock Volume  Final Concentration 
3M Tris 1.25 ml 
40% Acrylamide 2.5 ml   10% 
10 % SDS 100 µl 
99% TEMED 10 µl 
10% APS 75 µl 
ddH2O 6.1 ml 
 
4% Resolving gel  
Stock Volume  Final Concentration 
0.5M Tris 1.25 ml 
40% Acrylamide 1 ml   4% 
10 % SDS 100 µl 
99% TEMED 10 µl 
10% APS 50 µl 
ddH2O 7.59 ml 
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10 x running buffer 
Stock  Volume  Final Concentration 
Tris, MW=121.1 30.28 g   25 mM 
Glycine, MW=75.07 142.63 g   1.9 M 
10% SDS  100 µl   1 % 
ddH2O  to 1 L 
 
1 x running buffer 
Stock  Volume  Final Concentration 
10 x running buffer stock  100 ml   1 x 
ddH2O  900 ml 
 
Destain  
Stock  Volume  Final Concentration 
Acetic acid  200 ml   10% 
Methanol  600 ml   30% 
ddH2O   to 2 L 
 
Western blot analysis 
Transfer buffer   
Stock  Volume  Final Concentration 
Tris,   6.06 g   25 mM 
Glycine  28.83 g  192 mM 
Methanol  400 ml   20% 
ddH2O   to 2 L  
 
10 x TBS 
Stock  Volume  Final Concentration 
Tris 24.22 g   25 mM  
NaCl  80.06 g   1.37 M 
ddH2O     to 1 L. 
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1 x TBST  
Stock  Volume  Final Concentration 
10 x TBS   100 ml   1 x 
ddH2O     900 ml    
Tween 
®
20  1 ml 
 
5% Blocking buffer 
Stock  Volume  Final Concentration 
Fat free powder milk   5 g    5% 
1x TBST  100 ml 
. 
AMPK [pT172] ELISA 
100 Units/ml AMPK [pT172] standard 
Stock  Volume  Final Concentration 
AMPK [pT172] standard   100 Units/ml 
Standard diluent buffer 800 µl 
 
Dilution of AMPKα [pT172] standards 
Standard Add: Into 
100 Units/ml   
50 Units/ml 0.25 mL of 100 Units/mL  0.25 mL of Diluent buffer 
25 Units/ml 0.25 mL of 50 Units/mL 0.25 mL of Diluent buffer 
12.5 Units/ml 0.25 mL of 25 Units/mL 0.25 mL of Diluent buffer 
6.25 Units/ml 0.25 mL of 12.5 Units/mL 0.25 mL of Diluent buffer 
3.12 Units/ml 0.25 mL of 6.25 Units/mL 0.25 mL of Diluent buffer 
1.6 Units/ml 0.25 mL of 3.12 Units/mL 0.25 mL of Diluent buffer 
0 Units/ml 0.25 mL of diluent buffer An empty tube 
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Anti-rabbit IgG HRP working solution 
Stock  Volume  Final Concentration 
Anti-Rabbit IgG HRP (100x) 1 µl   1 x working solution 
HRP Diluent 1 ml 
Sufficient for analysis of 10 samples 
 
Wash buffer solution 
Stock  Volume  Final Concentration 
Washing buffer concentrate (25x) 25 ml   1 x working wash buffer 
ddH2O to 600 ml 
 
 
 
 
